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Mouse Mammary Tumor Virus (MMTV) is a member of the genus Betaretrovirus 
in the family Retroviridae. MMTV, which primarily induces mammary carcinomas, has 
been extensively used as a model system to study human breast cancers. Due to its complex 
organization similar to human retroviruses, such as human immunodeficiency virus type 
1(HIV-1) [12], studies of MMTV pathogenesis greatly aid in understanding viral 
interactions with the natural host immune system.  
MMTV encodes a 33 kDa regulatory protein, Rem, which is synthesized from a 
doubly spliced form of viral genomic RNA [23, 48]. The precursor Rem is targeted to the 
endoplasmic reticulum (ER) for translation and is cleaved by signal peptidase into an N-
terminal Signal Peptide (SP) and a C-terminal protein (Rem-CT) [50]. Previous studies 
have demonstrated that SP (also cleaved from envelope precursor protein) can manipulate 
the ER-associated degradation pathway (ERAD) and retrotranslocate to the cytoplasm 
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prior to nuclear entry to facilitate export of MMTV RNA [24]. SP thus has an analogous 
function to HIV-encoded Rev protein. The role of Rem-CT remains unknown. 
Cytidine deaminases belonging to the apolipoprotein B messenger RNA editing 
catalytic polypeptide (APOBEC/Apobec) family are restriction factors for human and 
mouse retroviruses, respectively, as well as for retrotransposons and some DNA viruses 
[129, 132, 141-150, 162-166]. Murine Apobec3 (mA3)-deficient mice are more susceptible 
to MMTV infection [179], yet no known MMTV-encoded antagonist of mA3 has been 
identified. MMTV requires replication through B and T lymphocytes [33, 34, 37], both of 
which express Apobec family proteins, prior to mammary gland infection and 
tumorigenesis [93, 97].  
Experiments were performed to address the role of Rem C-terminal sequences to 
antagonize Apobec enzymes and facilitate virus replication in vivo. Previous results have 
shown that mice infected with Rem-null MMTV developed mammary tumors with a lower 
incidence and increased latency compared to those infected with wild-type MMTV. 
Absence of Rem during in vivo infection resulted in lower proviral loads and increased 
mutations of the viral genome in mammary tumors. These differences were abolished in 
mice deficient for Activation-Induced Cytidine Deaminase (AID), a primordial member of 
the Apobec family that plays a role in shaping the adaptive immune response and 
development of human B-cell lymphomas. Tissue culture experiments revealed that Rem 
expression targets AID for proteasomal degradation. This study provides evidence that 
Rem is an HIV-Vif like protein and the first protein inhibitor of AID. In addition, these 
results suggest that Rem may antagonize other Apobec enzymes.  
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Chapter 1:  Introduction 
 
1.1 MOUSE MAMMARY TUMOR VIRUS (MMTV) 
1.1.1 MMTV history and classification 
MMTV is a complex murine retrovirus that was first reported in 1933 by Jackson 
Memorial Laboratory as an extrachromosomal factor associated with mammary tumors in 
inbred mice [1]. Later in 1936, Bittner demonstrated that this extra-chromosomal factor 
was transmitted through maternal milk, a virus then known as the “Bittner agent” [2]. 
Subsequently, MMTV isolated from milk of a high-mammary-tumor incidence mouse 
strain was shown to induce mammary tumors upon inoculation into a low-mammary-tumor 
incidence strain. This virus was also shown to have a reverse transcriptase (RT) [3, 4, 5]. 
Thus, MMTV was the first identified mammalian retrovirus that induced carcinomas. Since 
then MMTV has been used extensively as a model system to study human breast cancer 
[6].  
MMTV is classified as a member of the Retroviridae family. Viral particles are 
enveloped, spherical and contain a dimer of single-stranded positive-sense RNA that exists 
as a helical ribonucleoprotein (RNP) encapsidated by the nucleocapsid protein (NC) along 
with reverse transcriptase (RT) and integrase (IN).  The virus also has an icosahedral capsid 
composed of a single protein (CA), which surrounds RNP. The icosahedral capsid has an 
envelope consisting of a cellular phospholipid bilayer substituted with a viral envelope 
protein (Env) composed of a surface (SU) subunit and a transmembrane (TM) subunit. This 
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retrovirus exhibits a “B-type” morphology with prominent surface spikes, condensed core 
and has a characteristic particle size of 80-100 nm in diameter. Therefore, MMTV is the 
prototype for the genus Betaretrovirus based on its morphology [7, 8]. 
1.1.2 MMTV genome organization 
MMTV genome is a single-stranded, positive-sense RNA of approximately 9 kb in 
length. Both ends of the genomic RNA have a 15 bp direct repeat region (R). Internal to 
the R region, unique sequence regions of 120 bp (U5) and 1,200 bp (U3) are found at the 
5’ and 3’ ends, respectively. After infection, the MMTV RNA undergoes reverse 
transcription to yield a double-stranded viral DNA (provirus) that has long terminal repeats 
(LTRs) at both ends with the composition of U3-R-U5. The MMTV LTR contains hormone 
response elements (HREs), a mammary gland enhancer (MGE) and negative regulatory 
element (NRE), which determine hormone-response and tissue-specific transcription of the 
virus [9, 10, 11].   
Unlike simple murine retroviruses such as murine leukemia virus (MLV), MMTV 
has a complex genome organization that is similar to human retroviruses like human 
immunodeficiency virus (HIV) and human T-cell leukemia virus (HTLV) [12]. The 
MMTV RNA encodes the following viral genes from 5’ to 3’:  gag (group specific antigen), 
dut (dUTPase), pro (protease), pol (reverse transcriptase and integrase), env (envelope), 
rem (regulator of export/expression of MMTV mRNAs) and sag (superantigen). At least 
five transcripts are generated from integrated MMTV DNA (provirus) (Fig. 1.1).  
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Full-length unspliced MMTV RNA is transcribed from the U3 promoter in the 5’ 
LTR. This RNA is translated into Gag, Pro, Pol proteins or is packaged into virions as the 
viral genome (Fig. 1.2). Using a double ribosomal frameshift during genomic RNA 
translation, three polyprotein precursors, Gag (Pr77), Gag-Pro (Pr110), and Gag-Pro-Pol 
(Pr160), are generated. Gag is processed by the viral protease PR (encoded by pro) into the 
capsid (CA), nucleocapsid (NC) and matrix (MA) proteins, as well as other proteins of 
unknown function [13, 14, 15]. The Gag-Pro (Pr110) precursor is cleaved to yield the viral 
protease (PR) and the dUTPase; the role of the accessory protein, dUTPase in MMTV 
pathogenesis in not known. However, in retroviruses, such as the equine infectious anemia 
virus (EIAV), the dUTPase facilitates virus replication in non-dividing cells by maintaining 
an adequate nucleotide pool and excluding dU from proviral DNA [16]. Thus, the MMTV 
dUTPase activity could potentially aid in viral replication in non-dividing cells. The Gag-
Pro-Pol (Pr160) precursor is cleaved into RT (reverse transcriptase) and IN (integrase), 
which are needed to generate double-stranded proviral DNA and integration into the host 
chromosome, respectively [12]. A singly spliced mRNA is produced for expression of the 
envelope (env) gene, which encodes the Env precursor protein. Env is cleaved into surface 
(SU) and transmembrane (TM) domains by the host furin enzymes [12]. The extracellular 
SU domain has the receptor binding site (RBS) required to bind transferrin receptor-1 
(TfR1) on the cells, whereas the TM domain mediates viral entry by allowing fusion with 





                  
Figure 1.1: Diagram of the MMTV proviral genome and viral transcripts.  
The boxed regions at the 5’ and 3’ ends represent the LTRs. Viral promoters are shown  
in blue circles.  Four transcripts are generated from the LTR promoter: unspliced full-
length genomic RNA, which may be exported to the cytosol for translation into Gag, Gag-
Pro and Gag-Pro-Pol precursors. Alternatively, full-length RNA is processed into singly or 
doubly spliced mRNAs encoding Env, Sag or Rem. Sag may be translated from a singly 





Figure 1.2: MMTV virion morphology. 
A description of viral proteins and their functions is included in the text. 
 
In addition, the MMTV genome encodes for another accessory protein Sag 
(superantigen) and a regulatory protein Rem (regulator of export/expression of MMTV 
mRNA). Singly spliced sag mRNA is produced from the upstream U3 promoter as well 
as the intragenic env promoter [18, 19]. Sag expression is critical for transmission of the 
virus from lymphoid cells to the mammary gland [12, 20, 21]. Rem is translated from a 
doubly spliced version of the env gene. Rem is a precursor protein that is cleaved into a 
functional signal peptide (SP) and a C-terminal product of unknown function. SP 
facilitates export of unspliced MMTV mRNA from the nucleus to the cytosol as well as 
some post-export activities and thus functions analogous to HIV-encoded Rev protein [22, 
23, 24].  
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1.1.3 MMTV transmission and tissue tropism  
Horizontal milk-borne transfer from infected mothers to pups (exogenous virus) is 
the most common route of MMTV infection. The virus can also be inherited vertically after 
exogenous MMTV infection of germline cells (endogenous proviruses or Mtvs) [25, 26]. 
At least 10 different exogenous and more than 30 endogenous Mtvs have been identified 
[27, 28]. Most of the commonly used inbred mouse strains have two to eight endogenous 
MMTV-related proviruses, such as Mtv-6, 8 and 9 in BALB/cJ mice and Mtv-8, 9 and 17 
in C57BL/6 mice [29]. Most endogenous proviruses are defective in one or more genes and 
do not produce infectious virus. However, many Mtvs encode functional Sag, which 
induces intrathymic or peripheral deletion of Sag-reactive T cells and alters the mouse T-
cell repertoire [30, 31]. Proteins encoded by endogenous Mtvs may serve as self-antigens 
to generate partial tolerance against MMTV. Strains that lack Mtvs often show resistance 
to MMTV transmission and tumorigenesis [32]. BALB/cJ congenic mouse strain lacking 
all endogenous Mtvs was resistant to MMTV infection compared to wild-type BALB/cJ 
mice, by oral as well as intraperitoneal modes of infection. Thus, the presence of 
endogenous Mtvs potentially aids infection by exogenous MMTVs. Alternatively, specific 
endogenous Mtvs may function to protect against exogenous MMTV infection. Transgenic 
mice expressing C3H MMTV ORF protein in addition to their endogenous Mtvs, were 
resistant to exogenous infection by the C3H MMTV strain [25].   
MMTV acquired by newborn mice passes through the stomach and reaches the 
small intestine, where it first infects dendritic cells (DCs) and B cells within Peyer’s 
patches [33, 34] (Fig. 1.3). Following infection, the viral genome undergoes reverse 
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transcription, integration and transcription that leads to expression of the Sag protein. 
Major histocompatibility complex (MHC) class II proteins present Sag on the surface of 
infected antigen-presenting cells (APCs). Sag-presenting cells interact with CD4+ T cells 
expressing specific T-cell receptor (TCR) Vβ chains [35, 36]. Sag presentation initiates a 
helper T-cell response by priming Sag-reactive T lymphocytes, resulting in their rapid 
proliferation and release of cytokines. Cytokine release leads to a pool of actively dividing 
lymphoid cells that are susceptible to MMTV infection. These infected cells act as a 
reservoir for MMTV until the mice reach puberty, allowing mammary gland development. 
Actively dividing mammary epithelial cells then rapidly allow spread of the infection [37, 













 Figure 1.3: MMTV life cycle. 
MMTV is transmitted by either the exogenous or endogenous routes. Exogenous MMTVs 
are transmitted through the milk to the small intestine, where DCs are infected and viral 
Sag is presented to T cells. Sag-mediated release of T-cell cytokines allows MMTV 
infection of B and T cells that carry virus to the developing mammary gland during puberty. 










The tissue specificity of MMTV expression is tightly controlled by regulation of 
virus transcription. Studies have shown that at least two transcription factors, Cux1 and 
SATB1, can bind the NRE region within the LTR and suppress transcription in non-
mammary tissues [11, 40] (Fig. 1.4). SATB1 is absent in mammary tissues, whereas Cux1 
undergoes cleavage during late pregnancy, thus relieving transcriptional repression of 
MMTV [41]. The hormone-responsive element (HRE) provides transcriptional 
responsiveness to glucocorticoids and also other steroid hormones, e.g. androgens and 
progesterone during pregnancy and lactation, thereby maximizing the virus production in 
milk [42, 43]. In addition, the mammary gland enhancer (MGE) in the LTR binds multiple 
transcription factors expressed in mammary epithelial cells to further upregulate hormone-
induced transcription [44, 45]. 
 
 
Figure 1.4: Transcriptional control elements in the MMTV LTR.  
The transcription start site (+1) is located at the U3/R border and is denoted by an arrow. 
The mammary gland enhancer (MGE) is located at the 5’ end of the LTR within the U3 
region.  The negative regulatory region (NRE) has binding sites for Cux1 and SATB1. 
The hormone response element (HRE) has binding sites for multiple steroid receptors 




MMTV does not encode an oncogene, but instead causes mammary carcinomas by 
insertional mutagenesis near cellular proto-oncogenes. A number of common integration 
sites (CISs) have been reported in MMTV-induced tumors, particularly near Wnt and Fgf 
genes [46]. Because MMTV insertion into the cellular genome is relatively random, many 
integration events are required in mammary epithelial cells before insertion occurs near an 
appropriate proto-oncogene. The lack of targeted insertions and the subsequent selection 
of cells with MMTV-induced proto-oncogene activation results in a long tumor latency 
period of about six to nine months. Hence, mice that go through multiple rounds of 
pregnancy and lactation have higher levels of MMTV infection and an increased likelihood 
of developing mammary tumors [47].  
1.1.4 Regulator of export/expression of MMTV mRNA (Rem) 
Rem is a 301 amino-acid precursor protein that regulates the nuclear export of 
unspliced MMTV genomic RNA, as well as the post-export activities of all MMTV RNAs 
[23, 48]. Rem consists of a 98 amino-acid N-terminal signal peptide (SP) and a 203 amino-
acid C-terminus (Fig. 1.5). Rem is translated from a doubly spliced mRNA that overlaps 
with the env gene. Since Rem and Env share the same open reading frame, both proteins 
encode for SP. SP contains many functional elements, such as a nuclear localization signal 
(NLS), a nucleolar localization signal (NoLS), an arginine-rich motif (ARM) and a nuclear 
export signal (NES). All of these motifs are shared by other retroviral proteins, such as 




Figure 1.5: Diagram of the Rem precursor and its cleavage products.  
Rem is synthesized as a precursor, which is cleaved by signal peptidase at the ER 
membrane into SP and Rem-CT. Rem-CT is a truncated version of the envelope surface 
and transmembrane domains. 
 
SP generated from Env and Rem is longer than typical signal peptides and directs 
the precursor Rem to the endoplasmic reticulum (ER) membrane for translation. In the ER, 
signal peptidase cleaves the precursor protein into N-terminal SP and C-terminal protein 
(Rem-CT) [23, 50]. Uncleaved Rem is rapidly ubiquitylated, retrotranslocated to the 
cytoplasm, and subjected to ER-associated degradation (ERAD). In contrast, SP 
retrotranslocates to the cytoplasm, where it subverts ERAD to avoid proteasomal 
degradation [24]. Recent data from this laboratory indicates that SP is not ubiquitylated 
and binds to the p97 ATPase for membrane extraction into the cytosol [49]. Subsequently, 
SP traffics to the nucleus,where it binds unspliced MMTV mRNA for cytoplasmic export 
using the Crm1 pathway. In the cytoplasm, MMTV genomic RNA has two fates: 
translation into the unglycosylated viral proteins or incorporation into virus particles. 
Therefore, SP is a regulatory protein that is required for MMTV replication. 
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In contrast to SP, Rem-CT is a truncated version of Env and consists of the N-
terminal part of surface (SU) protein and the C-terminal part of the transmembrane domain 
(TM) (Fig. 1.2). Rem-CT has two distinct populations. A fraction of Rem-CT utilizes 
ERAD to retrotranslocate to the cytoplasm, whereas another fraction of the protein leaves 
the ER and follows a unique trafficking pathway. Although it lacks a transmembrane 
domain, a portion of Rem-CT does not follow the typical secretory pathway, but may use 
endosomal trafficking (Wendy Xu, unpublished data). The functions of Rem-CT are yet 
unknown.  
1.2 TYPE –B LEUKEMOGENIC VIRUS (TBLV) 
TBLV is a naturally occurring variant of MMTV that causes T-cell lymphomas in 
mice, typically with shorter latencies than MMTV-induced mammary tumors [51-55]. The 
main differences between the TBLV and MMTV genomes lie within their LTRs (Fig. 1.6). 
The TBLV LTR has a deletion of 443 nucleotides in the negative regulatory element 
(NRE). Binding of Cux1 and SATB1 transcription factors to the NRE represses viral 
expression in a number of cell types, including lymphoid cells [11, 41]. In addition, TBLV 
has a substitution of 124 nucleotides in the U3 region of LTR, which results in triplication 
of a 62-bp element comprised of sequences flanking the NRE deletion [56-63]. This 
triplicated region serves as a T-cell specific enhancer element and provides binding sites 
for transcription factors, such as c-Myb, Runx1 and GR [64-65]. Two unidentified protein 
complexes, nuclear factor A (NF-A) and nuclear factor B (NF-B), and the transcriptional 
coactivator Aly are also critical for TBLV T-cell enhancer function in tissue culture 
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experiments. Furthermore, the proto-oncogenes c-myc, tblvi1 and Rorc are three common 
integration sites identified in TBLV-induced lymphomas. Approximately 90% of TBLV-
induced tumors overexpressed c-myc gene as a result of insertional activation by TBLV 
LTR upstream or downstream of the promoter in either orientation [66-67].  
Deletion and substitution events within the TBLV LTR result in truncation of the 
sag open reading frame. This resulting truncated Sag protein retains the transmembrane 
region, part of the extracellular region, and the MHC-class II protein-binding motif. 
However, TBLV-encoded Sag lacks the C-terminal region that is required for its 
interaction with the TCR [68-69]. In contrast to MMTV-encoded Sag and its necessity for 
virus-induced mammary cancers, loss of TCR interaction is dispensable for induction of 
T-cell tumors in mice [70]. An early frameshift mutation within the TBLV truncated sag 
gene is compatible with the ability of the virus to cause T-cell lymphomas. Thus, TBLV 






        
Figure 1.6: Comparison of MMTV and TBLV LTRs.  
Both MMTV and TBLV LTRs consist of U3-R-U5 regions and have the transcription 
start site at the U3/R border.  The 5’ 18 bp and 3’ 44 bp sequences flanking the NRE 
constitute the triplicated T-cell enhancer in the TBLV-LTR enhancer. These sequences 
are shown in red and purple, respectively. 
 
1.3 APOBEC FAMILY OF CYTIDINE DEAMINASES 
The APOBEC family of enzymes deaminate cytidine to uracil on single-stranded 
substrates by a zinc-mediated hydrolytic mechanism [71-83]. This family has eleven 
members in humans: APOBEC1 and AID (tightly linked on chromosome 12), APOBEC2 
(chromosome 6), seven APOBEC3s (chromosome 22) and APOBEC4 (chromosome 1) 
(Fig. 1.7). AID and APOBEC2 have been identified in genomes of various bony fish and 
are considered the ancestral members, whereas the rest likely  appeared as a result of gene 
duplication [84-88]. APOBEC1 (apolipoprotein B messenger RNA editing catalytic 
polypeptide 1) was the first member of this family to be identified that catalyzes cytidine-
to-uridine editing of APOB mRNA in human intestine [89]. This modification generates a 
premature stop codon in the mRNA, giving rise to a truncated form of APOB protein called 
APOB48 that is essential for the transport of dietary fat [90]. APOBEC2 is expressed in 
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skeletal muscles and heart, whereas APOBEC4 is found in the testicles, but has no known 
deamination activity [91-92].  
Activation-Induced Cytidine Deaminase (AID) is another member of this family 
that acts on the immunoglobulin (Ig) locus during transcription in germinal center (GC) B 
cells [93-94]. This enzyme has two major effects that result in antibody affinity maturation: 
hypermutation of the Ig variable regions and class-switch recombination (see 1.3.1). Both 
APOBEC1 and AID are catalytically active inside the nucleus but are localized 
predominantly in the cytoplasm to limit access to the nuclear compartment. AID activity 
is regulated at various transcriptional and post-translational levels. Off-target effects of 
AID have been implicated in B-cell lymphomas [95]. Overexpression of AID has also been 
associated with development of T-cell lymphomas due to increased point mutations within 
T cell receptor and c-Myc gene, in transgenic mice constitutively and ubiquitously 




Figure 1.7: Schematic diagram of human APOBEC proteins.  
APOBEC proteins are drawn to scale and total number of amino acids is shown to the 
right of each protein. Catalytic domains or the zinc binding domains (CD) are shown in 
orange and are present in single or double copies.  For proteins with two CD copies, the 
N- and C-terminal domains are named CD1 and CD2, respectively [99]. 
 
APOBEC3 enzymes have been detected exclusively in mammals and restrict 
exogenous viruses as well as endogenous transposable elements (see 1.3.2). Humans have 
seven APOBEC3 (3A, 3B, 3C, 3D, 3F, 3G and 3H) genes that are expressed in a wide 
variety of tissues, whereas mice express only one copy of this gene [97]. APOBEC3 
proteins vary in their subcellular localization: APOBEC3B (A3B) localizes to the nucleus; 
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APOBEC3D (A3D), APOBEC3F (A3F) and APOBEC3G (A3G) are present in the 
cytoplasm; whereas APOBEC3A (A3A), APOBEC3C (A3C) and APOBEC3H (A3H) are 
found in both - nucleus and cytoplasm. [84, 98].  
 
1.3.1 Activation-Induced Cytidine Deaminase (AID) and virus restriction  
Activation-Induced  Cytidine  Deaminase  (AID)  is  a  key  regulator  of  B-cell  
diversity  and  plays  a  central  role  in development of a diverse repertoire of high affinity 
antibodies [100-102]. On encountering an antigen (Ag), B cells undergo division and  
diversification of antibody production in germinal centers (GC) of secondary lymphoid 
organs. AID catalyzes diversification of antibodies by somatic hypermutation (SHM) and 
class switch recombination (CSR) of Ig genes. This enzyme is known to have a preference 
for single-stranded DNA, which becomes accessible during transcription of the Ig loci 
[103]. Cytidine within the WRC or WRCY (W = A/T, R = purine, Y = C/T) motif context 
is preferred by AID for editing. During SHM, AID introduces point mutations in the 
antigen-binding variable region of an antibody. These  mutations  result  in antibodies  with 
increased  antigen  affinities, which allows B cells expressing edited B-cell receptors 
(BCRs) to proliferate and be subjected to positive selection  during  affinity  maturation.   
In contrast to hypermutation, which occurs on both Ig heavy and light chains, CSR  
occurs  exclusively  on  the  Ig  heavy  chain (IgH). AID-induced  mutations  in  the  Ig  
switch  regions located upstream of each IgH constant region are processed  as double-
stranded breaks. Processing results in recombination events that replace the constant region 
of the mu heavy chain (Cμ) with one of the downstream IgH  constant regions  (Cγ,  Cε,  
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Cα). This  event controls  antibody effector  functions  without  affecting their  antigen-
binding affinity [104-110]. Deficiency in SHM and CSR leads to Hyper-IgM syndrome, 
which is associated with increased susceptibility to infections [111]. However,  AID  has  
the  ability  to  target  non-Ig  genes  as  well,  with  cMyc-IgH translocations being 
prominent in B-cell malignancies. Thus, unregulated AID poses a threat to genomic 
integrity and hence is controlled at several levels including transcription, cellular 
localization and post-translational modifications [112-126]. At the level of mRNA 
stability, two miRNAs have been shown to regulate AID expression. The cellular 
distribution of AID is actively controlled by nuclear localization and nuclear export 
sequences. Various cofactors influencing nuclear access and cytoplasmic retention have 
also been identified. Post-translationally, proteasomal degradation and modifications 
involving phosphorylation affect the catalytic activity of AID.  
More  recent  research supports roles  for  AID  that are not  limited  to  B-cell  
differentiation and antibody diversification. AID  has been implicated  in  deamination  of  
methylated  cytidines  leading  to  demethylation  and  epigenetic  reprogramming [127]. 
Knockdown experiments showed that AID expression is required for OCT4 and NANOG 
gene demethylation and initiation of nuclear reprogramming during pluripotency in human 
somatic cells. A recent study has also shown AID expression in a unique subset of CD4+ 
T cells, although with no known function [128].  
AID has  been  shown  to  contribute  to  innate  immunity  by restricting the 
infectivity  of  certain  viruses, particularly those with a DNA genome or intermediate. 
Hepatitis B Virus (HBV) is a DNA-containing virus that replicates in hepatocytes through 
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an RNA intermediate using reverse transcriptase [129]. AID has been reported to recruit 
RNA exosomes to the HBV ribonucleoprotein complex resulting in degradation of HBV 
RNA [130]. In addition, Abelson MuLV, which transforms immature B cells, has been 
shown to induce AID expression in non-germinal center B cells. Virus infection triggers 
the DNA-damage response pathway resulting in restricted proliferation [131]. However, 
neither of these cases result in AID-induced viral mutations. On the other hand, some B-
cell tropic viruses such as Epstein-Barr Virus (EBV) and Kaposi’s sarcoma herpes virus 
(KSHV) can inhibit AID, which is activated as a result of viral infection. EBV upregulates 
a host microRNA (miR-155) that targets AID [133] and KSHV genome encodes for two 
microRNAs that antagonize AID [134]. Apart from exogenous viruses, AID has also been 
implicated in restriction of endogenous long interspersed endogenous element (Line-1 or 
L1) transposons [132] by a deamination-independent mechanism. AID has the highest 
expression in differentiated B cells, which are indispensable for establishment of MMTV-
infection [193]. Therefore, it is likely that MMTV has a mechanism for thwarting AID-
mediated viral restriction during replication in B cells.  
1.3.2 Human APOBEC3 and virus restriction  
Human A3D (hA3D), hA3F, hA3G and hA3H have been shown to restrict Vif-
deficient HIV-1(Fig. 1.8). In the absence of Vif, hA3 proteins form a cytoplasmic complex 
with HIV-1 Gag and get incorporated in the capsid of the budding viral particle [135-140]. 
After target cell infection, the viral capsid uncoats and RNA genome undergoes reverse 
transcription in the cytosol. Single-stranded intermediates on the viral minus-strand DNA 
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serve as a substrate for cytidine deamination by hA3 proteins that have been encapsidated 
in the viral particle. Uracil-containing minus strand complementary DNA (cDNA) 
functions as a template for second-strand synthesis and results in G to A mutations on the 
plus strand. Mutations lead to proviral instability or result in the introduction of stop 
codons, which affect the ability to produce a functional virus after integration into the host 
genome [141-145]. Studies have also shown that deamination-defective hA3G and hA3F 
can also restrict HIV-1 by binding genomic RNA and blocking access to reverse 
transcriptase [146-150]. However, HIV-1 Vif can counteract hA3 proteins by recruiting 
CBF-β to form a stable E3 ubiquitin ligase complex. This complex triggers 
polyubiquitylation and subsequent degradation of hA3 proteins, thus preventing virion 
incorporation in the producer cell [151-153]. All mammals encode for at least one A3 and 
other lentiviruses such as simian immunodeficiency virus (SIV), feline immunodeficiency 
virus (FIV) and bovine immunodeficiency virus (BIV) encode Vif proteins that degrade 
A3 enzymes of their respective hosts [154-156]. Therefore, viral antagonists of cytidine 





Figure 1.8: Model for HIV-1 restriction by human APOBEC3 proteins and Vif-mediated 
antagonism.  
In the virus producing cells, Vif acts as an adaptor molecule between the E3 ligase complex 
and specific hA3 proteins, leading to polyubiquitylation (shown by red circles) of the 
deaminases and their subsequent degradation by the 26S proteasome. In the absence of Vif, 
different hA3 proteins get incorporated in the budding viral particle along with viral RNA. 
After fusion of the viral particle with a target cell and initiation of reverse transcription 
(RT), hA3 proteins deaminate cytidines to uracils on single-stranded viral minus strand 
cDNA. This uracil on the template strand results in incorporation of adenine on the 
complementary plus strand, giving rise to guanine to adenine mutations. These 
hypermutated cDNAs are either targeted for degradation or integrated into the host 
genome. Many integrated proviruses have multiple stop codons that prevent viral protein 




Human T-cell leukemia virus type-1 (HTLV-1) has been shown to be restricted by 
hA3 enzymes via both deaminase-dependent and independent mechanisms. However, 
HTLV-1 is considerably more resistant than HIV-1 to hA3D, hA3F and hA3G, although 
HTLV-1 also is susceptible to hA3A and hA3B [157-159]. HTLV-1 does not encode a Vif 
accessory protein that targets deaminases for degradation [160-161]. Instead, a unique C-
terminal extension of HTLV-1-encoded nucleocapsid (NC) protein has been demonstrated 
to antagonize A3 enzymes by preventing their encapsidation in the viral particle. In 
addition to exogenous retroviruses, A3 proteins inhibit mobility of LTR-containing 
retroviruses (HERVs) as well as non-LTR retrotransposons (LINEs and SINEs) in humans 
by sequestration in the cytoplasm [162-164]. Apart from retroelements, studies have also 
documented hA3-induced mutations in DNA viruses, e.g. Hepatitis B virus (HBV) and 
Human papilloma virus (HPV) [165-166]. 
1.3.3 Murine Apobec3 and virus restriction  
Several studies have described the effects of murine Apobec3 (mA3) on different 
strains of the gammaretrovirus Murine Leukemia Virus (MuLV). Mice lacking mA3 have 
10-100 fold higher levels of Friend (F)-MuLV infection in both spleen and bone marrow 
[167], suggesting that this enzyme is active in lymphoid cells. In addition, the mA3 locus 
has also been shown to encode for Recovery from Friend Virus 3 (Rfv3) gene, which has 
been associated with regulating the neutralizing antibody response to Friend virus (FV) 
infection [168]. FV is a complex of the defective spleen focus forming virus (SFFV) and 
the non-defective F-MuLV [177-178]. Studies of another gammaretrovirus that infects 
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lymphoid cells,  Moloney (M)-MuLV, revealed that infection of mA3-knockout mice 
accelerated T-cell lymphoma induction. Establishment of infection was significantly 
delayed in spleens and bone marrow-derived cells compared to the same tissues of mA3-
expressing C57BL/6 mice [169]. Moreover, infectivity of M-MuLV with packaged mA3 
was reduced further by mA3 expressed in the target cells that were being infected [170]. 
Interestingly, in experiments carried out in AKR strain of mice that express an endogenous 
MuLV (AKV), mA3-mediated restriction was accompanied by G to A hypermutation of 
the viral genome [171].   The mA3 enzyme deaminates cytidines in the TYC sequence 
motif (Y = T/C). Significant levels of cytidine deamination by mA3 have not been reported 
for any of the exogenous MuLVs [172-173]. 
Although mA3 caused G to A mutations in HIV in co-expression experiments in 
tissue culture, this enzyme is resistant to Vif-mediated degradation [174]. Multiple studies 
have shown that MuLVs are more resistant to mA3 than to hA3 enzymes. Primary 
protection of MuLVs from mA3 inhibition is contributed by a glycosylated form of the 
capsid precursor protein Gag (Glyco-Gag). This longer form of Gag has an additional 88 
amino acids at the N-terminus and has been reported to confer stability to the virus capsid. 
Glyco-Gag-mutant viruses cause the capsid to be loosely formed and more accessible to 
mA3-mediated blocks to reverse transcription [170,175]. A second layer of protection is 
provided by MuLV protease, which cleaves the mA3 allele encoded by BALB/cJ mice 
within exon 5. C57BL/6 mice encode mA3 (mA3exon5) that is resistant to this cleavage 
[176]. These results suggest that there are strain-specific differences in mA3-mediated 
MuLV restriction.   
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1.4   MMTV RESTRICTION BY MURINE APOBEC3  
The first evidence of mA3-mediated viral restriction was demonstrated in vivo by 
studying MMTV [179]. Murine Apobec3 (mA3) mRNA is detectable in lymphoid cells, 
macrophages and dendritic cells. However, the highest levels of mA3 have been reported 
in lymphoid cells, which are known to be indispensable for establishment of MMTV 
infection in vivo. Mice with targeted deletion of the murine Apobec3 gene on C57BL/6 
background have higher levels of MMTV DNA and are more susceptible to infection by 
the RIII strain of MMTV [179].  Very low levels of mA3-induced G to A mutations were 
detected in these MMTV sequences, suggesting a deamination-independent means of 
restriction [180-181].  
BALB/cJ mice encode a longer mA3 isoform consisting of 9 exons, whereas 
C57BL/6 mice lack exon 5 and encode a ~3.6 kDa smaller protein [182-184].  Additionally, 
BALB/cJ mice express lower levels of mA3 compared to C57BL/6 mice and hence may 
be less restrictive to murine viruses. Virions isolated from mammary tissues of MMTV-
infected mice showed that both allelic variants of mA3 are incorporated into the particle 
and retain their deamination activity. Subsequently in vitro infection assays revealed that 
the major means of mA3-mediated restriction of MMTV was by inhibition of reverse 
transcription and not cytidine deamination [180]. 
Further, mA3 expression was observed in mammary epithelial cells (MECs), where 
it can get incorporated in the virus particle to restrict milk-borne transmission. Experiments 
conducted to test the infectivity of virus isolated from milk revealed that virus from mA3- 
knockout mice infected cells at higher levels than that isolated from wild-type mice [182]. 
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Hence, mA3 potentially restricts MMTV at various steps during virus replication and 
transmission in vivo.  
1.5 RATIONALE FOR THIS STUDY  
MMTV is a betaretrovirus that causes mammary carcinomas in mice and has been 
successfully used as a model system to study human breast cancer. Unlike many other 
murine viruses, MMTV has a complex genome organization similar to human retroviruses 
such as HIV and HTLV. Apart from structural proteins that form the virus particle, MMTV 
encodes additional accessory and regulatory proteins that facilitate its pathogenesis.  
Prior to causing mammary gland tumors by insertional mutagenesis, MMTV 
establishes its infection in the lymphoid population. Dendritic cells, B cells and T cells 
serve as a reservoir for the virus until mice reach puberty, and the virus has access to 
actively dividing mammary epithelial cells [37]. MMTV has evolved ways to both evade 
and use the host immune system. Thus, studying the viral pathogenesis will help us identify 
mechanisms of innate and adaptive immune evasion.  
MMTV encodes a 33 kDa regulatory protein, Rem. Signal peptide (SP) generated 
from the N-terminus of Rem functions analogous to HIV- Rev protein. SP binds to a cis-
acting element within the viral RNA and aids in exporting it to the cytoplasm. SP is also 
produced from MMTV envelope protein. Hence, this raises the question of how expression 
of full - length Rem can provide an advantage to the virus in vivo.  
Previous studies have shown that MMTV replicates more efficiently in the absence 
of the restriction factor murine apobec3 (mA3). However, viral sequences analyzed from 
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these studies lacked detectable levels of mA3-induced cytidine deamination. We were 
motivated to infect BALB/cJ and C57BL/6 mice with virus that lacks Rem expression in 
order to ascertain if Rem affects the innate responses to MMTV infection. 
This study demonstrates that absence of Rem makes the MMTV genome more 
susceptible to mutations occurring in motifs known to be recognized by the Apobec family 
members, namely AID and mA3. An independent study performed with the thymotropic 
variant TBLV also showed the same mutational phenotype in BALB/cJ mice, suggesting 
that Rem is an antagonist of AID and mA3 possibly in different cell types. Our results thus 
point towards a Vif-like function of Rem in protecting the viral genome from the activity 
of cytidine deaminases in the lymphoid population. Although AID has been shown to 
restrict retroviruses, these experiments provide the first example of a retroviral genome 
mutated by AID. Surprisingly, AID-knockout (AID-KO) mice demonstrated reduction in 
motifs known to be recognized by mA3, implicating AID as a regulator of other cytidine 
deaminases. Since AID overexpression has been associated with multiple human cancers, 
elucidation of the mechanism by which Rem antagonizes AID will be useful for treatment 







Chapter 2:  Materials and Methods 
 
2.1 CELL LINES 
  XC rat fibroblast cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
(Invitrogen, Carlsbad, CA) supplemented with 5% heat-inactivated (30 min at 56°C) fetal 
bovine serum (FBS) (Sigma),  100 Units/ml penicillin, 100 μg/ml streptomycin 
(Invitrogen), 2 mM L-glutamine and 50 μg/ml gentamycin sulfate (Elkins-Sinn, Inc., 
Cherry Hill, NJ). Derivation of stable XC/MMTV transfectants has been described 
previously [185-186]. Jurkat human T-lymphoma cells were maintained in suspension 
using Roswell Park Memorial Institute (RPMI) 1640 medium (Invitrogen) containing 5% 
FBS, 100 Units/ml penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine and 50 μg/ml 
gentamycin sulfate.  Human embryonic kidney cells (293T) were maintained in DMEM 
containing 10% FBS, 100 Units/ml penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine 
and 50 μg/ml gentamycin sulfate. All cell lines were maintained at 37°C in a humidified 
atmosphere containing 7.5% CO2.  
2.2 MICE 
        Weanling (4-6 weeks old) mice were injected intraperitoneally with 2 X 107 XC cells 
producing MMTV-WT or MMTV-SD or 2 X 107 Jurkat T cells producing TBLV-WT or 
TBLV-SD [70,185]. Prior to inoculation into mice, the cells were washed twice with 
phosphate-buffered saline (PBS) and resuspended in 500 μl of PBS. Aliquots of the cells 
inoculated into mice were analyzed by Western blotting to verify the expression of viral 
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proteins. XC cells stably transfected with MMTV were induced for 24 h before injection 
into mice by supplementing the culture medium with 10−6 M dexamethasone (Sigma 
Chemical Laboratories, St. Louis, MO). Jurkat cells were not treated with Dex since they 
lack functional glucocorticoid receptors. AID-KO mice on the BALB/cJ background were 
derived by 10 backcross generations with AID-KO mice on the C57BL/6 background 
obtained from Dr. T. Honjo, Kyoto University [93] (kindly provided by Dr. M. 
Nussenzweig, Rockefeller University).  A total of 80 markers were used to distinguish 
between BALB/cJ and C57BL/6 backgrounds. All mice were confirmed to have the correct 
genotype by PCR typing of tail DNA as described [32]. Injected mice were monitored for 
the appearance of T-cell lymphomas or mammary carcinomas at least weekly, and the 
resulting tumors were harvested and stored frozen at -70oC. AID-GFP transgenic mice on 
the C57BL/6 background were obtained from Jackson Laboratories [218]. Mouse breeding, 
maintenance, inoculations and PCR typing were performed by Mary Lozano. All animal 
experiments were approved by the UT Austin IACUC. 
2.3 GENOMIC DNA PREPARATION 
       Tissue fragments obtained by crushing frozen tissue were incubated in lysis buffer [75 
mM NaCl, 20 mM Tris-HCl, pH 7.4, 25 mM EDTA, pH 8.0, 0.5% (w/v) SDS, 100 μg/ml 
fresh proteinase K] at 37°C for 1 to 2 days. If the lysates were very viscous, additional 
proteinase K and lysis buffer were added during this incubation. The lysates were then 
extracted with phenol-chloroform, and the aqueous phase was collected in a separate tube. 
DNA was adjusted to 0.2 M NaCl and precipitated using 70% ethanol. The genomic DNA 
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was spooled out into an Eppendorf tube using a Pasteur pipette, and the majority of ethanol 
was removed. The DNA was re-suspended in a solution of 10 mM Tris-HCl, pH 7.4 and 
0.1 mM EDTA (TE 10:0.1) and stored at 4°C.  
2.4 PLASMID PREPARATION 
 Large-scale plasmid preparations were performed by alkaline lysis and cesium 
chloride (CsCl) gradient centrifugation.  Briefly, 500 ml of Luria-Bertani (LB) broth [1% 
tryptone w/v, 0.5% yeast extract (w/v), 0.5% NaCl w/v, pH 7.4] containing appropriate 
antibiotic was inoculated with 25 ml of an overnight culture of bacterial transformant 
growth in LB. The culture was grown in a two liter Erlenmeyer flask and grown at 37°C 
with shaking. Bacteria were pelleted by centrifugation (Avanti J-E centrifuge, Beckman) 
at 7,000 rpm in a JA10 rotor (Beckman) for 10 min at 4°C. The pellet was resuspended in 
7 ml of Solution I (50 mM glucose, 25 mM Tris-HCl, pH 8.0, and 10 mM EDTA) and 
transferred to a 50 ml conical tube.   Lysozyme [stock concentration of 10 mg/ml (Sigma)] 
was added to a final concentration of 1 mg/ml, and the suspension was incubated at room 
temperature (RT) for 10 min. Sixteen ml of freshly prepared Solution II [0.2 N NaOH and 
1% sodium dodecyl sulfate (SDS)] was added to lyse the bacterial cells by gently inverting 
the tube 3-4 times, followed by a 10 min incubation at RT. The alkaline reaction was 
neutralized by adding 12 ml of cold Solution III (3 M potassium acetate, pH 4.8, in glacial 
acetic acid) and mixed thoroughly by shaking the tube several times. The mixture was 
incubated on ice for 10 min, followed by centrifugation in an Allegra X-15R centrifuge 
(Beckman Coulter) at 3,800 rpm for 30 min at 4°C. Chromosomal DNA was pelleted and 
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the supernatant was filtered through cheesecloth into a new 50 ml conical tube. Isopropanol 
was added to the tube and incubated at RT for 15 min. DNA was precipitated by 
centrifugation at 3,800 rpm for 30 min at RT in an Allegra X-15R centrifuge. The DNA 
pellets were washed with 70% ethanol and air dried for 10 min.  Pellets were resuspended 
in 3.5 ml of 10 mM Tris-HCl, pH 7.4, and 10 mM EDTA (TE 10:10). CsCl gradient 
ultracentrifugation was then used to purify the DNA by removing RNA and proteins.  
CsCl (4.7 g) and ethidium bromide (EtBr) (0.78 ml of a 5 mg/ml solution) were 
added to DNA dissolved in TE 10:10. Insoluble debris (RNA and protein) was removed by 
centrifugation at 3,500 rpm for 15 min at 4°C in an Allegra X-15R centrifuge. The 
supernatant was transferred to a Beckman Optiseal tube, and the suspension was separated 
by centrifugation in a Beckman L7-65 ultracentrifuge at 50,000 rpm for 18 h at 20°C using 
an NVT 65.2 rotor. The plasmid band was transferred to a 15 ml conical tube with a help 
of an 18 gauge needle and EtBr was extracted 3-4 times until a clear solution was obtained. 
The extraction was done by using 2 volumes G-50 buffer (20 mM Tris-HCl, pH 7.4, 0.1 M 
NaCl, and 2 mM EDTA) saturated n-butanol. Subsequently, DNA was precipitated by 
addition of ice-cold 100% ethanol, 0.2M NaCl and centrifugation at 3,800 rpm for 30 min 
at 4°C in an Allegra X-15R centrifuge. Following a 70% ethanol wash and air-drying, the 
DNA pellet was resuspended in 2 ml of TE (10:10). RNA contaminants were removed by 
incubation at 37°C for 30 min with 100 μg/ml of pancreatic RNase A (Sigma) and 200 U 
of RNase T1 (Sigma). The solution was incubated with 100 µg/ml of proteinase K (Sigma) 
in the presence of 0.5% SDS for 30 min at 37°C. Following phenol:chloroform extraction, 
the solution was dialyzed using a 10,000 molecular-weight cut-off (MWCO) Slide-A-
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Lyzer® dialysis cassette (Pierce, Rockford, IL) against 10 mM Tris-HCl, pH 7.4 and 1 mM 
EDTA (TE 10:1) with three buffer changes. Plasmid DNA was recovered by ethanol 
























Infectious MMTV-expressing and dexamethasone-inducible 
molecular clone [186]. 
pHYB MMTV-SD 
pHYB-MMTV-WT molecular clone carrying a mutation in the 
second Splice Donor (SD) site [185]. 
pHYB TBLV-WT Infectious TBLV-expressing molecular clone [70]. 
pHYB TBLV-SD 
pHYB-TBLV-WT molecular clone carrying a mutation in the 
second Splice Donor (SD) site [70]. 
GFP-Rem N-terminally EGFP-tagged Rem expression plasmid. 
Rem 
Untagged Rem expression plasmid made by introducing Rem 
coding region into EGFPN3 vector lacking GFP. 
pGL3 Firefly luciferase reporter vector from Promega 
pHMRLuc Rem-responsive Renilla luciferase reporter vector [23] 
pcDNA3.1 Control vector from Addgene used in transfection assays. 
CMV MMTV - 
WT 
CMV promoter-driven infectious MMTV-expressing molecular 
clone obtained from Dr. Farah Mustafa [189]. 
CMV MMTV - 
SD 
CMV MMTV-WT molecular clone carrying a mutation in the 
second Splice Donor (SD) site. 
mA3-HA 
HA-tagged C57BL/6 Apobec3 cloned into pcDNA3.1 obtained 
from Dr. Nathaniel Landau [174]. 
mAID-GFP 
C-terminally GFP-tagged murine AID expression plasmid 
obtained from Dr. Frederick Alt [187]. 
pcDNA3.1-mAID 
Untagged murine AID expression plasmid cloned from pMX-
AID. 
pMX-AID 
Untagged AID expressed in a retroviral vector provided by Dr. 
Kevin McBride [188]. 
pHITG 
CMV promoter-driven VSV-G expression plasmid provided by 
Dr. Glen Gaulton. 
pHIT60 
CMV promoter-driven Moloney MuLV Gag-Pol expression 
construct provided by Dr. Glen Gaulton. 
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2.5 PCR  
DNA extracted from tumors induced by MMTV-WT and MMTV-SD were used 
for PCR with primers env7254(+) (5’-ATCGCCTTTAAGAAGGACGCCTTC T-3’) and 
C3H LTR420(-) (5’-GATTCATTTCTTAACATAGTAAC-3’) for the envelope region. 
For DNA extracted from tumors induced by TBLV-WT and TBLV-SD, LTR9604(-) (5’-
GGA AACCACTTGTCTCACATC-3’) was used as the reverse primer for env gene 
amplification. PCR parameters were: 94oC for 1 min, then 10 cycles at 94oC for 10 sec, 
53oC for 30 sec, and 68oC for 2 min followed by 25 cycles of 95oC for 15 sec, 50oC for 30 
sec, and 68oC for 2 min, and a final incubation at 68oC for 7 min. The c-Myc gene was 
amplified using primers c-Myc(+) (5’-ATGCCCCTCAACGTGAACTT-3’) and c-Myc(-) 
(5’-AGGAGGTCCATCCAACCTCT-3’). PCR parameters were: 94oC for 1 min, then 35 
cycles at 94oC for 30 sec, 58oC for 30 sec, and 68oC for 2 min, and a final incubation at 
68oC for 5 min. All reactions were performed with JumpStart RED Accutaq LA 
polymerase (Sigma-Aldrich) in the supplied buffer, 500 ng of tumor DNA, 50 pmol of each 
primer, and 0.5 mM deoxynucleoside triphosphates in 20 µl.     
Semi-quantitative PCR was performed with 50ng DNA. Mtvr2(+) (5’-TCTGGG 
ATCCGCTTCCTCAT-3’) and Mtvr2(-) (5’-CCAGTCCTTGGCCCTCATTTA-3’) or 
pol4235(+) (5’-GAAGAGAGCAATAGCCCTTG-3’) and pol5835(-) (5’–
GATGATGTAGTGCGTGGC-3’) primers were used for PCR. Levels of the pol gene 
product were normalized with levels of Mtvr2. DNA from MMTV-infected BALB/cJ mice 
was used as a control. 
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Proviruses from MMTV and TBLV-induced tumors amplified with virus specific 
primers were cloned using pGEM–T Easy Vector System 1 (Promega). Briefly, PCR 
products were separated on 1% agarose gel and the appropriate band was purified with 
DNA Clean and Concentrator Kit (Zymo Research). Purified DNA amplicons were ligated 
to pGEM-T Easy Vector with T4 DNA Ligase at 16oC overnight. The ligation mixture was 
transformed into E.coli (DH5alpha) and DNA was extracted from resultant colonies using 
GenElute Plasmid Miniprep Kit (Sigma). DNA was sequenced with env (7254+) and env 
(8506-) (5’ – GCACTTGGTCAAGGCTCTTCG – 3’) primers.  
Table 2.2: Summary of primers used in this study. 
Primer Sequence 
env7254(+) 5’ATCGCCTTTAAGAAGGACGCCTTCT 3’ 
C3H LTR420- 5’GATTCATTTCTTAACATAGTAAC 3’ 
LTR9604(-) 5’GGAAACCACTTGTCTCACATC 3’ 
c-Myc(+) 5’ATGCCCCTCAACGTGAACTT 3’ 
c-Myc(-) 5’AGGAGGTCCATCCAACCTCT 3’ 
Mtvr2(+) 5’TCTGGGATCCGCTTCCTCAT 3’ 
Mtvr2(-) 5’CCAGTCCTTGGCCCTCATTTA 3’ 
env(8506-) 5’ GCACTTGGTCAAGGCTCTTCG 3’ 
pol4235(+) 5’GAAGAGAGCAATAGCCCTTG 3’ 
pol5835(-) 5’GATGATGTAGTGCGTGGC 3’ 
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2.6 RNA EXTRACTION AND RT-PCR 
Total RNA was extracted from tissue culture cells using the TRI Reagent 
(Molecular Research Center, Inc). Culture medium was removed, and one ml of TRI 
Reagent was added directly to the culture dish to lyse the cells. Lysate was transferred to 
an Eppendorf tube, pipetted several times to homogenize and incubated for 5 minutes to 
allow complete dissociation of the nucleoprotein complexes. Chloroform (0.2 ml) per 1 ml 
of TRI Reagent was added, followed by a 2–3 min incubation. Samples were then 
centrifuged for 15 min at 12,000 × g at 4°C. The mixture separates into a lower red phenol-
chloroform phase, an interphase, and a colorless upper aqueous phase. The aqueous phase 
containing the RNA was transferred to a new tube. Isopropanol (0.5 ml) per 1 ml of TRI 
Reagent was added to the aqueous phase and incubated for 10 min. RNA was concentrated 
by centrifugation at 12,000 × g at 4°C for 30 min. After washing with 75% ethanol, the 
pellet was resuspended in 100 to 200 μl of diethyl pyrocarbonate-treated water (0.1% 
DEPC treatment followed by autoclaving).  
 Purified RNA (10 μg) was treated with 3U of amplification-grade DNase I 
(Invitrogen) and 0.5 U of RNaseOUT RNase inhibitor (Invitrogen) for 4 h at 37ºC. The 
DNase I reaction was stopped by the addition of 5 μl of 25 mM EDTA and incubation at 
72ºC for 15 min. Reverse transcription reactions contained oligo primer poly(dT17) and 
deoxynucleotide triphosphates (dNTPs) at final concentrations of 2.5 pmol/μl and 1 mM, 
respectively. The mixture was then boiled for 5 min, followed by immediate incubation on 
ice for 5 min. The RNA was reverse transcribed with 400 U of Moloney murine leukemia 
virus (M-MLV) reverse transcriptase (Invitrogen), 5 U of RNaseOUT, and 10 mM 
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dithiothreitol in a 50 μl reaction mixture for 1 h at 37ºC. The complementary DNA was 
used with primers C3H 230(+) (5’-GTG AAT TCC ATC ACA AGA GCG GAA CGG 
AC-3’) and C3H LTR420(-) (5’-GAT TCA TTT CTT AAC ATA GTA AC-3’) in reactions 
with JumpStart REDTaq Reaction Mix (Sigma-Aldrich).   The PCR parameters were: 94oC 
for 2 min and then 30 cycles of 94oC for 20 sec, 55oC for 30 sec, and 68oC for 6 min and 
an 8 min extension at 68oC.  Reactions were analyzed on 1% agarose gels and stained with 
EtBr prior to visualization using an AlphaImager (Alpha Innotech). 
2.7 TRANSFECTIONS  
Calcium Phosphate Precipitation: HEK 293 and 293T cells were transfected by the 
calcium phosphate method. One day (24 h) before transfection 5 x 105 cells were seeded 
in 6-well tissue culture plates in 2 ml of media. On the day of transfection, total 6 μg DNA 
was mixed with 10 μl of CaCl2 (final concentration of 0.25 M) and the volume was adjusted 
to 100 μl with water. This solution was added dropwise to a second tube containing 100 μl 
of 2X-HBS, pH 7 (280 mM NaCl, 10 mM KCl, 1.5 mM Na2HPO4·2H2O, 12 mM dextrose, 
50 mM HEPES) while vortexing. The mixture was incubated at RT for 15 – 20 min and 
added to the cells dropwise. At 6 to 8 h post-transfection media was changed to remove the 
calcium phosphate precipitate. Cells were harvested after 48 h. 
Lipofectamine:  Lipofectamine 3000 (Invitrogen) was also used for transfection of 
293T cells. The day before transfection 106 cells were seeded in 6-well plates. For each 
transfection, 3 μg of DNA was mixed with 2 μl/μg of P3000 Reagent, and DMEM without 
additives was added for a final volume of 125 μl.  In a separate tube, 5 μl of Lipofectamine 
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3000 was added to DMEM without additives for a final volume of 125 μl. The diluted DNA 
was then added to diluted Lipofectamine at 1:1 ratio and incubated for 20 min at RT. The 
DNA-Lipofectamine 3000 Reagent complexes were added to cells dropwise.  Cells were 
harvested after 48 - 72 h. 
Electroporation: Jurkat T cells and XC rat fibroblast cells were transfected by 
electroporation. On the day of transfection, 1 x 107 cells were resuspended in 400 μl of 
serum-free RPMI. DNA (20-40 μg) was added to this mix and transferred to a 4-mm gap 
cuvette. A Gene Pulser II (Biorad) was used to electroporate Jurkat and XC cells at 260V, 
950 μF and 260V, 750 μF, respectively. Cells were replated in 60 mm plates with 5 ml of 
complete media after 10-15 minutes of incubation at RT. MMTV expression in XC cells 
was induced by addition of 10-6M Dex for 24 h. Cells were harvested at 48 h. 
2.8 PREPARATION OF RETROVIRUS-CONTAINING CULTURE SUPERNATANTS  
Culture supernatants were aspirated from 293T cells transfected in two 6-well 
plates at 48 and 72 h post-transfection. After a short centrifugation at 4,000Xg to remove 
any cell contaminants, the supernatant was passed through a 0.45 micron filter and 
incubated overnight with one-third volume of RetroX concentrator (Takara) at 4oC. Virus 
was pelleted by centrifugation at 1,500Xg for 45 minutes at 4oC and resuspended in PBS. 
For protease treatment, half of the PBS resuspension was incubated with subtilisin (Roche) 
at a final concentration of 10 μg/ml for 1 h at 37oC [190-191]. Subsequently, the samples 
were analyzed by Western blotting. 
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2.9 RETROVIRAL TRANSDUCTION 
Pseudotyped mAID-expressing virus was produced in HEK293T cells by co-
transfecting retroviral plasmids pMX-AID along with pHITG (expressing VSV 
glycoprotein G) and pHIT60 (expressing MuLV Gag-Pol) (see Table 2.1). Two days post-
transfection, culture supernatants were centrifuged thrice at 524Xg for 5 min in a Beckman 
Allegra X-15R centrifuge to remove cell debris. Pseudotyped virus was concentrated using 
a Beckman SW55Ti rotor and centrifugation at 100,000Xg for 1 h at 40C. Supernatants 
were decanted, and viral pellets were resuspended in PBS. Concentrated virus was 
transduced into Jurkat cells by spinoculation at 800Xg for 1 h at RT in the presence of 8 
μg/ml polybrene to obtain an MOI >1. Transduced cells were grown in the presence of 2 
μg/ml puromycin for 5-6 days.  
2.10 REPORTER GENE ASSAYS 
        Firefly and Renilla luciferase luminescence was measured with the Dual-Luciferase® 
Reporter Assay System (Promega) according to the manufacturer’s instructions. 
Transfected cells were washed with 1X PBS and lysed in 1X Passive Lysis Buffer 
(Promega) by three cycles of freezing at -80ºC for 20 min and thawing in a 37ºC water 
bath. The lysates were clarified by centrifugation at 4,000 rpm in a Beckman Coulter 
Microfuge 18 Centrifuge for 10 min at RT. Bio-Rad Protein assay system was used to 
quantitate protein concentration. A total of 20 - 40 μg of lysate was used to obtain readings 
for both firefly and Renilla luciferase using a Turner TD-20e luminometer (Turner Designs, 
Inc., Sunnyvale, CA) that was set to 0 delay and 10 sec integration. Luciferase Assay 
Reagent II (LAR II) (Promega) (50 μl) was added to the sample, and the firefly luciferase 
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activity was determined. The Renilla luciferase activity was determined after the addition 
of 50 μl Stop and Glo Reagent (Promega). The firefly luciferase was expressed in relative 
light units (RLUs), and the relative values were normalized to 100 μg of protein. 
2.11 EX VIVO INDUCTION OF AID 
Spleens were removed aseptically and single cell suspensions were made in 5 ml 
of wash solution containing 1X PBS and 1% FBS. Cells were subjected to centrifugation 
at 1,200 rpm for 7 min. Red blood cells were then lysed in 3 ml of Red Blood Lysis Solution 
(9 parts NH4Cl and 1 part Tris-HCl pH 7.65) for 5 min at RT. Wash solution (20 ml) was 
added and cells were pelleted again at 1,200 rpm for 7 min. The resulting pellets were re-
suspended in 2 ml of wash solution and filtered through a 40 micron strainer into 35mm 
Petri-dishes. Cells were then counted, plated at 5 x 105/ml and grown in stimulation media 
(RPMI 1640 with L-glutamine from Sigma, 1% Antibiotic/anti-mycotic solution from 
Gibco, 1 mM Sodium Pyruvate from Sigma, 10% FBS from Biowest, 50 uM 2-
mercaptoethanol from Invitrogen, 5 ng/ml IL-4 from Sigma and 20 ug/ml LPS from Sigma. 
Maximum AID expression was observed at day 4. 
2.12 WESTERN BLOTTING  
Whole cell extracts were prepared by adding either one volume of 2X-SDS-loading 
buffer [250 mM Tris-HCl, pH 6.8, 20% glycerol, 2% sodium dodecyl sulfate (SDS), 5% 
β-mercaptoethanol, 0.2% bromophenol blue] to cells in one volume of phosphate-buffered 
saline (PBS) or one volume of 6X-SDS loading buffer (0.35 M Tris-HCl, pH 6.8, 10% 
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SDS, 36% glycerol, 0.6 M DTT, 0.012% bromophenol blue) to cells in five volumes of 
PBS. Samples were boiled for 5 min for protein denaturation. 
Total denatured protein (10 to 100 μg) from the extracts was resolved in 10 or 12% 
polyacrylamide gels containing 1% SDS and transferred to Optitron 0.45 μm nitrocellulose 
membranes in Western transfer buffer [39 mM glycine, 48 mM Tris base, 1% SDS, 20% 
(v/v) methanol] overnight at 120 mA at 4ºC. The membrane was incubated with 5% nonfat 
dry milk in Tris-Buffered Saline Tween-20 (TBS-T) buffer (20 mM Tris-HCl, pH 7.4, 137 
mM NaCl, 0.1% Tween 20) for 1 h. The membrane was then incubated with different 
antibodies diluted in TBS-T buffer or in TBS-T buffer containing 5% nonfat dry milk for 
4 h at RT or overnight at 4ºC followed by three washes with TBS-T buffer for 10 min each. 
The membrane then was incubated with horseradish peroxidase-tagged secondary 
antibodies diluted in TBS-T buffer containing 5% nonfat dry milk for 1 to 2 h and washed 
three times with TBS-T buffer for 10 min each. Binding of the secondary antibody was 
detected using the Western Lightning Enhanced Chemiluminescent Reagent (Perkin 
Elmer, Wellesley, MA) as recommended by the manufacturer.  
2.13 ANTIBODIES 
GFP, Actin, AID and HA-specific antibodies were obtained from Clontech, 
Calbiochem, Cell Signaling and BioLegend respectively. SP-specific antibody was 
prepared by immunization of rabbits following standard protocols of Cocalico Biologicals 
(Reamstown, PA) [24]. MMTV Gag-specific monoclonal antibodies were kindly provided 
by Dr. Tanya Golovkina (University of Chicago)[192]. Incubation with all primary 
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antibodies was performed at 4oC overnight, whereas secondary antibody incubations were 
performed for 1 h at RT.  
2.14 STATISTICAL ANALYSIS 
         Statistical significance for luciferase assays was determined using the two-tailed 
Student’s t test. Statistical differences between tumor development induced by the wild-
type and mutant viruses and Kaplan-Meier survival curves were calculated using SPSS 
software. Differences in distribution of mutations/clone were assessed by non-parametric 
Mann-Whitney tests. Correlation analysis was performed by calculating Spearman’s 
correlation coefficient. Mann-Whitney tests and Correlation analysis was performed using 
















Retroviruses such as HIV-1 and MuLV have been shown to encode for regulatory 
proteins that antagonize the APOBEC/Apobec family of restriction factors during their 
replication within T lymphocytes [151, 170, 194-198].  Previous studies have shown that 
MMTV requires B and T cells for efficient transmission to the mammary gland [25, 193]. 
MMTV elicits a Sag-mediated T-cell response, but manages to evade the immune system 
prior to inducing mammary carcinomas. MMTV infection of mice deficient for murine 
Apobec3 (mA3) revealed accelerated mammary tumorigenesis and increased viral loads 
relative to wild-type C57BL/6 mice [179]. Currently, no MMTV-encoded protein has been 
shown to antagonize mA3.  
MMTV Rem protein is synthesized as a precursor at the endoplasmic reticulum 
(ER) membrane, and gets cleaved into an N-terminal signal peptide (SP) and a C-terminal 
protein (Rem-CT) [24]. Rem is a doubly spliced version of the singly spliced MMTV env 
mRNA, which also generates SP in the same open reading frame. SP has functional 
similarities to HIV-Rev [22, 23]. However, function of the full-length Rem protein is still 
unknown. In this study, I assessed the potential role of full-length Rem (or the cleavage 
product Rem-CT) as an accessory factor in vivo, to antagonize the murine Apobec family 





3.2.1 MMTVs lacking Rem expression have reduced incidence and increased latency 
of mammary tumors. 
MMTV-encoded Rem is synthesized as a precursor protein at the ER membrane 
[22]. The precursor Rem gets cleaved by the signal peptidase into an N-terminal SP, which 
is a Rev-like protein. SP is also generated from the Env protein [23, 24]. Another Rem 
cleavage product, Rem-CT, is a truncated version of the Env surface (SU) and 
transmembrane (TM) domains (Fig. 1.5). To confirm expression of Rem-CT, 293 cells 
were transfected with either untagged or tagged Rem-expression plasmids. Both plasmids 
yielded a cleaved C-terminal product that could be detected with Rem-CT antibody, 
although the tagged version had higher steady-state levels (Fig. 3.1). 
 
Figure 3.1: Western blotting of extracts from 293 cells transfected with untagged or 
tagged Rem expression constructs.  
Positions of the tagged Rem precursor and cleaved Rem-CT (tagged and untagged) are 
shown in the upper panel after incubation of Western blots with Rem-CT-specific antibody.  
The bottom panel shows the same extracts with actin-specific antibody. This blot was 
performed by Nimita Halani. 
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To determine the function of Rem C-terminal sequences in vivo, an infectious 
MMTV provirus harboring a mutation within the env splice donor site (MMTV-SD) was 
used (Fig. 3.2). The SD mutation consists of 7 non-contiguous bases (GGGGTGAGT to 
GGACTCTCA) resulting in a single valine to leucine change in the Env protein. Previous 
studies have shown that this mutant produces normal viral RNA levels has and no 
replication defects in tissue culture [185].  Ablation of the SD2 site prevents expression of 
Rem, Rem-CT, as well as Sag from the intragenic env promoter. However, Sag expression 
from the upstream LTR promoter remains unaffected.  
 
 
Figure 3.2: Strategy for generation of Rem-null MMTV provirus.  
The thick gray boxes are long terminal repeats (LTRs); the thinner boxes show open 
reading frames. The rem coding region is shown in red. The SD2 mutation (designated by 
an X) eliminates the downstream SD site needed to generate the doubly spliced rem mRNA 




Western blot analysis of XC (rat fibroblast) cells stably expressing MMTV-WT and 
MMTV-SD showed no difference in the levels of intracellular Gag protein expression (Fig. 
3.3A). As expected RT-PCR for viral mRNAs indicated loss of rem upon introduction of 
the SD mutation (Fig. 3.3B). Additionally, to determine whether introduction of the SD2 
mutation resulted in decreased SP activity, we co-transfected either MMTV-WT or 
MMTV-SD with pHMRluc vector in XC cells. This vector has been shown to 
quantitatively measure the post-export activities of MMTV SP and to be dependent on the 
presence of a functional Rem-responsive element [23]. Similar levels of SP activity were 
observed for both wild-type and mutant proviruses (Fig. 3.4). Therefore, the loss of Rem 
expression has no effect on the level and processing of Env in tissue culture.  
 
Figure 3.3: MMTV-WT and MMTV-SD produce equivalent amounts of Gag precursor in 
tissue culture cells & MMTV-SD proviruses lack rem mRNA synthesis. 
A) Stably transfected XC rat cells expressing MMTV-WT or MMTV-SD were used to 
harvest cell extracts. Westerns were incubated with CA-specific (upper panel) or Gapdh-
specific (lower panel) antibody. Western blotting with CA-specific antibody shows similar 
amounts of Gag precursor (Pr77) expression in cell extracts.  B) RNA from XC fibroblast 
cells stably expressing MMTV-WT or MMTV-SD and from untransfected cells was used 




To determine whether Rem C-terminal sequences serve an accessory function in 
vivo, BALB/cJ mice were injected intraperitoneally with 2x107 XC cells expressing the 
MMTV-WT or MMTV-SD provirus. As expected from previously published experiments 
[185], MMTV-SD infection resulted in fewer mammary tumors with an increased latency 
compared to MMTV-WT (Fig 3.5).  
 
           
Figure 3.4: MMTV-WT and MMTV-SD have similar levels of SP activity.  
Transient transfections of MMTV-WT and MMTV-SD were performed in XC rat 
fibroblasts.  Cells were transfected and incubated in the presence or absence of 
dexamethasone (Dex) as indicated to stimulate the hormone-inducible MMTV LTR. SP 
activity as measured by a Renilla luciferase reporter assay is unaffected by the Rem-null 
MMTV provirus. NS = not significant. Transfection of the CMV-promoter-driven Rem 
expression plasmid was used as a positive control. The majority of SP activity is derived 





                          
Figure 3.5: BALB/cJ mice infected with the Rem-null (MMTV-SD) virus develop 
mammary tumors with lower incidence and increased latency compared to tumors 
induced by MMTV-WT.   
Kaplan-Meier plots reveal a difference in mammary tumor development between mice 
infected with MMTV-WT (blue line) or MMTV-SD (green line) (see p-value). 
 
Next, to assess the role of Rem in restricting levels of MMTV infecting the 
mammary gland, proviral loads were determined in tumors obtained from wild-type and 
Rem-null virus-induced mammary tumors. Despite many attempts, none of the primer pairs 
tested could distinguish the infecting exogenous MMTV from the endogenous Mtvs from 
BALB/cJ mice in quantitative PCRs (data not shown). Therefore, semi-quantitative PCRs 
were performed on three independent tumors from different mice with primers for the 
MMTV polymerase region, with pol(4235+) and pol(5835-) and compared to DNA from 
uninfected BALB/cJ mice. The Mtvr2 (Mouse mammary tumor virus receptor homolog 2) 
gene was used as a normalization control. Wild-type and Rem-null MMTV-induced tumors 
had increased proviral loads compared to DNA from uninfected mice (Fig. 3.6). Based on 
the ability of these primers to detect one diploid copy each of endogenous Mtvs 8 and 9 in 
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BALB/cJ mice [32], these results suggest that MMTV-induced tumors had acquired 4 to 7 
haploid proviruses. Viral loads were higher in MMTV-WT induced tumors compared to 
those induced by MMTV-SD (p<0.05), consistent with restriction of viruses infecting the 
mammary gland as a consequence of the Rem-null mutation.                            
 
 
                                                
Figure 3.6: MMTV-SD-induced mammary tumors have reduced viral DNA levels 
relative to those in MMTV-WT-induced tumors.   
PCRs were performed using DNA from three mammary tumors derived by inoculation of 
three independent BALB/cJ mice with either MMTV-WT or MMTV-SD and compared 
with uninfected BALB/cJ DNA containing endogenous Mtv proviruses. Statistical 
significance between columns is indicated by an asterisk (p<0.05). 
 
 
3.2.2 Proviral clones from mammary tumors induced by MMTVs lacking Rem 
expression show increased viral genome mutation.  
The cytidine deaminase mA3 has been shown to restrict MMTV infection in vivo 
[179], but none of the MMTV-encoded proteins are known to antagonize this enzyme. 
Since fewer tumors were induced by MMTV-SD and these tumors had a lower viral load, 
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I tested whether the presence of Rem facilitates MMTV pathogenesis by inhibiting the 
activity of mA3. If Rem is an mA3 antagonist, then the absence of Rem would be expected 
to increase G to A mutations on the viral genome plus strand. 
 DNA was extracted from five independent mammary tumors induced by MMTV-
WT as well as five MMTV-SD-induced tumors. The MMTV envelope gene was amplified 
using virus specific primers (env 7254+ and env 420-). Individual clones were obtained for 
Sanger sequencing, which allows analysis of longer regions of the viral genome that will 
distinguish between endogenous Mtvs and exogenous virus integrations. Longer reads were 
also suitable for differentiating between proviral clones that had retained the original 
mutation in the SD site relative to proviruses that had lost the mutation by recombination 
with endogenous Mtvs as observed previously [185]. Since analysis of the proviral loads 
indicated that ~ 4 to 7 copies of the virus were acquired, only five clones from each 
mammary tumor were sequenced to avoid duplicate sampling. Sequencing results showed 
that the plus strand of the proviral clones obtained from MMTV-SD induced tumors had 
increased transition as well transversion mutations, compared to clones from tumors 
induced by MMTV-WT. The largest increase consisted of C to T transitions on the plus 
strand of the proviruses. Previous reports have shown that mA3-induced cytidine 
deamination of the proviral minus strand during reverse transcription results in G to A 
mutation of the viral plus strand [97, 151] (Table 3.1).   
Since non-G to A mutations on the plus strand are not typically observed as a result 
of mA3 activity, the involvement of additional cytidine deaminases was analyzed. 
Replication in B cells is an absolute requirement for efficient transmission of MMTV to 
 50 
the mammary gland. The cytidine deaminase AID is preferentially expressed in germinal 
center B cells [199] and has been shown to antagonize retrotransposon insertions [132]. 
AID-induced cytidine deamination is often followed by error-prone DNA repair activity 
resulting in additional transition and transversion mutations [200,201]. Thus, mutations 
observed in MMTV proviruses were analyzed for the WRC motif, reported to be a “hot-
spot” for AID-induced base changes within immunoglobulin gene variable regions [202].   
The frequency of cytidine mutations in the WRC context was almost five-fold 
higher in the Rem-null MMTV-SD-induced tumors (Table 3.1). The frequency of cytidine 
mutations in the SYC context, which has been described as an AID “cold spot” and less 
frequently mutated [203,204], were also higher in the proviruses obtained from MMTV-
SD tumors. However, the fold-increase was lower than that observed for the WRC motif.  
Cytidine changes in two other sequence contexts (TYC and ATC) also were analyzed.  
Analysis of the frequency of changes in the TYC motif, typical of those induced by mA3 
[110, 171], showed mutations only in the proviruses obtained from the MMTV-SD-
induced tumors.  TYC mutations were not detected in MMTV-WT proviruses. Mutations 
in the ATC context also have been associated with mA3 in vitro [180], and analysis of 
these mutations indicated a slight increase in MMTV-SD proviruses compared to MMTV-
WT proviruses. Because of the wide variability in number of mutations/clone, I could not 
analyze this tabular data statistically (see below). Nevertheless, these data are consistent 
with increased mutations by mAID and/or mA3 after loss of the SD site.   
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Table 3.1: Mutation frequency in MMTV-WT and MMTV-SD proviruses from 
BALB/cJ mammary tumors by Sanger sequencing. 
          1 Mutations/number of clones.  Based on Sanger sequencing of 1,100 bp of the  
       plus strand of the proviral env gene clones obtained from five independent  
       BALB/cJ tumors induced by MMTV-WT (n=25) or MMTV-SD (n=32).  
 
Interestingly, about 22% of the clones obtained from MMTV-SD-induced tumors 
showed loss of the introduced SD mutation as noted in a previous study [185]. All of these 
clones had acquired the SD site sequence exactly matching that of the wild-type virus 
(GGACTCTCA to GGGGTGAGT), suggesting selection pressure for splice site 
restoration in vivo. Because of the number of base mutations, reversion of the SD site 
mutation is most likely a result of a recombination event between the endogenous Mtvs and 
exogenous virus, as reported previously in MMTV-induced mammary tumors [28, 185, 
205]. MMTV-Rem protein had not been discovered when such recombination events were 
first reported. Hence, occurrence of this event had been attributed solely to the requirement 










G to A 0.36 1.28 3.6 
A to G 0.56 1.22 2.2 
C to T 0.08 0.66 8.3 
T to C 1.08 1.38 1.3 
Transition 2.08 4.54 2.2 
Transversion 0.56 1.00 1.8 
WRC 0.12 0.59 4.9 
SYC 0.08 0.28 3.5 
TYC 0.00 0.53 - 
ATC 0.12 0.19 1.6 
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Since a large variability in the number of mutations per clone was observed, a non-
parametric t-test (Mann-Whitney) was employed to determine statistically significant 
differences in the distribution of mutations/clone across different groups. Proviruses with 
reverted SD-sites had higher numbers of WRC and ATC motif mutations compared to 
proviruses with SD-site mutations that had not undergone recombination with endogenous 
Mtvs (Fig. 3.7A and D). In contrast, mutations within SYC and TYC motifs were not 
significantly different regardless of the SD-site reversion (Fig. 3.7B and C). Despite having 
higher mutations, MMTV-SD recombinant clones lacked stop codons within the env open 
reading frame. This result further suggests that selection of replication-competent virus 
during MMTV pathogenesis in vivo (Fig. 3.8) results in altered sag and/or rem expression. 
Therefore, these data indicate that reduction of one or both of these genes through the SD 
mutation reduces the ability of MMTV to induce mammary tumors as well as the proviral 






     
 
 
Figure 3.7: Mutational analysis of the proviral envelope gene from BALB/cJ mammary 
tumors induced by MMTV-WT or MMTV-SD.   
Number of C mutations within different motifs on either proviral strand is given for each 
clone. Number of clones (n) is indicated.  Sequences were obtained from independent 
clones from five tumors in different animals. (A) Number of mutations/clone in the WRC 
motif typical of AID mutation hotspots. (B) Number of mutations/clone in the SYC motif. 
(C) Number of mutations/clone in the TYC motif typical of mA3 mutation hotspots. (D) 
Number of mutations/clone in the ATC motif. Statistical significance by non-parametric 





Figure 3.8: MMTV-SD recombinant proviruses lack stop codons.  
Amino acid differences between the MMTV-WT and MMTV-SD recombinant proviruses 
in the env gene as determined for individual clones by Sanger sequencing. Increased viral 
gene mutations in the absence of Rem yield recombinants that lack stop codons within the 




3.2.3 Viral genome hypermutation of Rem-null virus is also observed in tumors 
induced by the Sag-independent variant TBLV. 
 Although the sag transcript may be generated from the upstream LTR promoter in 
the SD site mutant MMTV [185], increased mutation of the viral genome could be 
attributed to loss of Sag expression from the env promoter or from loss of Rem expression.  
To distinguish between the roles of these two accessory proteins, the thymotropic variant 
TBLV was used for in vivo experiments. TBLV is a naturally occurring MMTV strain that 
encodes a truncated non-functional sag gene [64, 65, 70]. Despite this truncation TBLV 
can cause lymphomas in mice. Similar to results with MMTV-WT and MMTV-SD, SP 
activity was not reduced in Rem-null TBLV proviruses (TBLV-SD) whereas expression of 
rem mRNA was blocked (Fig. 3.9A and 3.9B). Also, no difference in virus production was 









Figure 3.9: TBLV-WT and TBLV-SD have similar levels of SP activity & TBLV-SD 
proviruses lack rem mRNA synthesis.  
A)Transient transfections of TBLV-WT and TBLV-SD in human Jurkat cells. SP activity 
as measured by a Renilla luciferase reporter assay is preserved by the Rem-null TBLV 
provirus. Transfection of CMV-promoter-driven Rem expression plasmid was used as a 
positive control. The asterisk indicates significance (p<0.05). B) RNA from human Jurkat 
cells stably expressing either TBLV-WT or TBLV-SD and from untransfected cells was 
used for RT-PCRs. Primers were designed for the TBLV LTR (upper panel) or Gapdh 
(lower panel). These experiments were performed by Almas Ali. 
 





                
Figure 3.10: TBLV-WT and TBLV-SD produce equivalent amounts of virus in tissue 
culture.  
Stably transfected Jurkat cells expressing TBLV-WT or TBLV-SD were used to harvest 
supernatants or for preparation of cytosolic extracts. Western blotting shows similar 
amounts of Gag expression in whole-cell lysates (left panel) and released virus in 
supernatants (right panel) from cells transfected with expression plasmids for TBLV-WT 
or TBLV-SD.  Western blots were incubated with CA-specific or actin-specific antibody.  
Arrows indicate the positions of cleaved capsid (CA) or capsid precursor (Pr77Gag). 
 
Thus, to confirm the role of Rem in preventing increased mutation of the viral 
genome, BALB/cJ mice were injected intraperitoneally with 2x107 Jurkat cells stably 
expressing TBLV-WT or TBLV-SD. Contrary to MMTV-SD, Rem-null TBLV did not 
result in reduced or delayed tumors (Fig. 3.11A). However higher proviral loads were 
maintained in TBLV-WT induced tumors compared to TBLV-SD tumors (Fig. 3.11B). 
This result suggests that differences in tumor incidence and latency are a Sag-dependent 
phenomenon as reported previously [185]. Rem C-terminal sequences on the other hand 
may play a role at an earlier step during the virus life cycle, by antagonizing Apobec 
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enzymes in the lymphoid population prior to transmission of the virus to the mammary 
gland [206].  
 
    
 
Figure 3.11: TBLV-SD-induced thymic tumors have reduced viral DNA levels relative to 
TBLV-WT-induced tumors.   
(A) Kaplan-Meier plots for T-cell lymphoma development in BALB/cJ mice injected with 
TBLV-WT (blue line) or TBLV-SD (red line) are shown with p-value. (B)  TBLV-SD-
induced thymic tumors have reduced viral DNA levels relative to TBLV-WT-induced 
tumors.  PCRs were performed using DNA from three thymic tumors derived by 
inoculation of three independent BALB/cJ mice with either TBLV-WT or TBLV-SD. PCR 
product levels were compared with uninfected BALB/cJ DNA containing endogenous Mtv 
proviruses. Statistical significance between columns is indicated by an asterisk (p<0.05). 




To determine whether the absence of Rem results in increased proviral mutations, 
DNA was extracted from thymic tumors induced by wild-type or mutant TBLV. The env 
gene was amplified by PCR using virus-specific primers. Three independent TBLV-WT 
tumors as well as TBLV-SD-induced tumors were analyzed. After cloning of PCR 
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products, sequencing analysis revealed that the TBLV genome was also subjected to higher 
mutations in the absence of Rem. The C to T transitions showed the highest increase 
between the wild-type versus SD mutant proviruses, although the G to A transitions had 
the highest frequency (Table 3.2) as observed for MMTV. The increased frequency of 
mutations was not observed for the cellular gene c-Myc, which also was amplified from 
TBLV-WT and TBLV-SD-induced tumors (Table 3.3).  
Table 3.2: Mutation frequency in TBLV-WT and TBLV-SD proviruses from 
BALB/cJ thymic tumors by Sanger sequencing. 
          1 Mutations/number of clones.  Based on Sanger sequencing of 1,100 bp of the  
       plus strand of the proviral env gene clones obtained from three independent  


















G to A 2.02 2.98 1.5 
A to G 0.60 1.27 2.1 
C to T 0.08 0.73 9.1 
T to C 0.86 1.53 1.8 
Transition 3.56 6.51 1.8 
Transversion 0.10 0.71 7.1 
WRC 0.26 0.67 2.6 
SYC 0.14 0.69 4.9 
TYC 0.84 1.65 2.0 
ATC 0.18 0.47 2.6 
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Table 3.3: Mutation frequency in the c-Myc gene from TBLV-induced BALB/cJ 
thymic tumors by Sanger sequencing. 
1 Mutations/number of clones. Based on Sanger sequencing of 720 bp of the plus-strand 
of the c-Myc gene clones (~40) obtained from three independent BALB/cJ T-cell tumors 
induced by TBLV-WT or TBLV-SD.  
 
Since unlike MMTV-induced tumors, TBLV induces polyclonal tumors, high-
throughput sequencing was used also for the analysis of proviruses.   Averaged reads also 
revealed that TBLV-SD proviruses had numerous G to A and C to T as well as other 
transition mutations relative to TBLV-WT proviruses (Table 3.4A).  A similar result was 
observed for a portion of the TBLV polymerase gene (Table 3.4B), but not cellular Gapdh 
























G to A 0.10 0.10 1.0 
A to G 0.30 0.30 1.0 
C to T 0.10 0.10 1.0 
T to C 0.20 0.20 1.0 
Transversions 0.10 0.02 0.2 
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Table 3.4: Averaged mutations from proviral and cellular genes from TBLV-
induced BALB/cJ thymic tumors by Illumina sequencing. 
 
Table 3.4A. Averaged mutations in the TBLV-WT versus TBLV-SD proviral envelope 
genes from T-cell tumors by Illumina sequencing 
Mutation TBLV-WT Tumors1 TBLV-SD Tumors1 Fold Increase 
G to A 12 52 4.3 
A to G 2 17 8.5 
C to T 0 14 >14.0 
T to C 4 12 3.0 
Transversions 2 4 2.0 
Table 3.4B. Averaged mutations in the TBLV-WT versus TBLV-SD proviral polymerase 
genes from T-cell tumors by Illumina sequencing 
Mutation TBLV-WT Tumors2 TBLV-SD Tumors2 Fold Increase 
G to A 13 35   2.7 
A to G 3 15   5.0 
C to T 1 15 15.0 
T to C 1 16 16.0 
Table 3.4C.  Averaged mutations in the Gapdh gene from TBLV-WT and TBLV-SD-
induced T-cell tumors by Illumina sequencing 
Mutation TBLV-WT Tumors3 TBLV-SD Tumors3 Fold Increase 
G to A 15 15 1.0 
A to G 1 1 1.0 
C to T 17 17 1.0 
T to C 4 4 1.0 
Transversions 3 3 1.0 
1 Number of mutations in ~60,000 reads averaged at each base within 1,371 bp of the plus-
strand of proviral envelope genes in three independent BALB/cJ tumors induced by TBLV-
WT or TBLV-SD using Illumina sequencing of PCR products.  Mutations were identified 
as ≥ 2% different from the reference sequence. 
2 Number of mutations in ~60,000 reads averaged at each base within 1,619 bp of the plus-
strand of the proviral polymerase genes in three independent BALB/cJ tumors induced by 
TBLV-WT or TBLV-SD using Illumina sequencing of PCR products.  Mutations were 
identified as those that were ≥ 2% different from the reference sequence.  No transversions 
were observed. 
3 Number of mutations in ~60,000 reads averaged at each base within 581 bp of the plus-
strand of the Gapdh genes in three independent BALB/cJ tumors induced by TBLV-WT 
or TBLV-SD using Illumina sequencing of PCR products.  Mutations were identified as 





To determine whether SD site reversion occurred in T-cell tumors, I also analyzed 
the frequency of this event in TBLV-SD proviruses. Although the frequency of SD 
reversion was lower (9%) than in MMTV-SD proviruses (22%), both types of reversion 
were consistent with recombination with endogenous Mtvs [185], i.e., all 6 of the 
introduced nucleotide mutations were corrected to the sequence of the endogenous Mtvs 
Mtv8 or Mtv9 proviruses found in BALB/cJ mice [32]. In contrast to MMTV-SD proviruses 
from mammary tumors, 80% of the TBLV-SD recombinants had stop codons in the env 
gene (Fig. 3.12). Since TBLV is an end-point virus that is not transmitted to the mammary 
gland, this lymphomagenic virus may be subjected to a lower selective pressure during 
replication in lymphoid cells. Nevertheless, selection for reversion of the TBLV-SD site 
occurs within lymphoid cells. More importantly, since TBLV is a Sag-independent virus, 
SD reversion points towards a requirement of Rem protein to allow efficient virus 





Figure 3.12: TBLV-SD recombinant proviruses have stop codons.  
Amino acid differences between TBLV-WT and TBLV-SD- recombinant proviruses in the 
env gene as determined for individual clones by Sanger sequencing. Unlike MMTV-SD 
recombinants, increased viral gene mutations in the absence of Rem result in increased stop 
codons within the env open reading frame of the TBLV-SD-recombinant provirus.  Stop 
codons are shown with an asterisk and are boxed in red. 
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 To determine the specificity of other mutations within the TBLV env gene, I 
analyzed proviral mutations occurring in motifs recognized by various Apobec enzymes. 
The distribution of mutations/clones was significantly different between TBLV-SD 
mutants and recombinants in the WRC, SYC and TYC motifs, but not the ATC motif. (Fig. 
3.13). Both MMTV and TBLV proviral clones showed increased TYC but not WRC motif 
mutations, regardless of the SD-site reversion. These results suggest that these mutations 
are a result of the activity of distinct enzymes, perhaps in different cell types. Correlation 
analysis was also conducted to examine the relationship between the SD-site reversion in 
MMTV and TBLV proviruses and the number of mutations in different motifs. Calculation 
of Spearman’s coefficient revealed a significant correlation between the number of 
recombinants and mutations in each of the motifs (Fig. 3.14).  In addition, Mtv8 and Mtv9 
are known to be expressed in lymphocytes, suggesting that recombination and mutagenesis 
occurs in these cells [27]. Since TBLV is not transmitted to the mammary gland, these data 
are consistent with multiple Apobec-type mutations, including those induced by AID and 




Figure 3.13: Mutational analysis of the proviral envelope gene from BALB/cJ thymic 
tumors induced by TBLV-WT or TBLV-SD.  
Number of C mutations within different motifs on either proviral strand is given for each 
clone. Number of clones analyzed (n) is indicated.  Sequences were obtained from 
independent clones from five tumors in different animals. (A) Number of mutations/clone 
in the WRC motif typical of AID mutation hotspots. (B) Number of mutations/clone in the 
SYC motif. (C) Number of mutations/clone in the TYC motif typical of mA3 mutation 
hotspots. (D) Number of mutations/clone in the ATC motif. Statistical significance by non-
parametric Mann-Whitney tests is indicated on the scatter plots.   
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Figure 3.14: Correlation analysis of the number of recombinants and sum of mutations in 
different motifs from MMTV and TBLV-induced tumors.  
(A-D) Spearman’s correlation coefficient (r) indicating high correlation between number 
of recombinants and sum of mutations in WRC, TYC, SYC and ATC motifs, respectively. 
Correlation coefficient p-values are shown on the graph. 
 
 
Several attempts also were made to study AID-induced mutations of the viral 
genome in tissue culture. Jurkat cells stably producing TBLV-WT or TBLV-SD were 
transduced with murine leukemia virus vectors expressing murine AID (pMX-AID). 
Transduced cells were grown in puromycin to select for AID-positive cells and DNA was 
extracted after ten days to analyze for mutations within the TBLV env gene. PCRs were 
performed with TBLV env-specific primers, and products were cloned. Sequencing 
analysis of individual clones revealed no difference in mutations in the absence and 
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presence of Rem expression (Table 3.5). Because Jurkat cells are of human origin and do 
not express the receptor for TBLV [64], these cells release virus after transfection, but 
cannot be re-infected. This result suggests that the increased mutations observed in the in 
vivo studies do not occur in cells releasing viral particles, but in the target cells following 
reverse transcription. 
Table 3.5: Mutation frequency in TBLV-WT and TBLV-SD proviruses from AID-




1Mutations/number of clones.  Based on Sanger sequencing of 1,100 bp of the plus-strand 
of the proviral env gene clones obtained from pMX-AID and TBLV expressing Jurkat cells 
(TBLV-WT (n=34) or TBLV-SD (n=32).  
 
 
3.2.4 Most viral genome hypermutation in tumors induced by Rem-null virus is 
abolished in AID-KO BALB/cJ mice. 
 To further define the involvement of AID in restricting MMTV infection, AID-KO 
BALB/cJ mice were injected with 2x107 XC cells expressing MMTV-WT and MMTV-
SD. These mice were generated by crossing AID-KO C57BL/6 mice from Dr. Honjo [93] 
to BALB/cJ mice, genotyping to select for AID-KO litter and followed by ten similar 
backcrosses with BALB/cJ. Although the appearance of mammary tumors was slightly 












G to A 1.20 0.90 0.8 
A to G 0.70 0.70 1.0 
C to T 0.150 0.13 0.9 
T to C 1.10 1.10 1.0 
Total 3.20 2.80 0.9 
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BALB/cJ AID-KO mice with the Rem-null virus as opposed to results from MMTV 
infection of wild-type BALB/cJ mice (Figs. 3.15A, 3.16). Additionally, unlike infection of 
wild-type BALB/cJ mice with wild-type and Rem-null MMTV, analysis of proviral loads 
did not yield a significant difference between MMTV-WT and MMTV-SD-induced tumors 
in AID-KO BALB/cJ mice (Fig. 3.15B). This result strengthens the conclusion that 
differences in viral load are a Rem-dependent phenomenon whereas reduction in tumor 
incidence is a Sag-mediated effect.  
 
       
Figure 3.15: MMTV-WT and SD-induced mammary tumors in BALB/cJ AID-KO mice 
have different incidences and latencies, but similar viral loads.  
(A) Kaplan-Meier plots for mammary tumor development in AID-KO BALB/cJ mice 
injected with MMTV-WT (blue line) or MMTV-SD (green line) are shown with p-value. 
(B)  Proviral loads in MMTV-WT and MMTV-SD-induced mammary tumors relative to 
endogenous Mtv proviruses in uninfected AID-KO mice.  PCRs were performed using 
DNA from three mammary tumors derived by inoculation of three independent BALB/cJ 
AID-KO mice with either MMTV-WT or MMTV-SD. Results were compared with 
uninfected BALB/cJ DNA containing endogenous Mtv proviruses. Statistical significance 
between columns is indicated by an asterisk (p<0.05). NS = not significant.  Although the 
values were not significantly different (NS), the trend indicated that MMTV-SD proviral 




       
 
Figure 3.16: The incidence and latency of MMTV-induced mammary tumors does not 
differ between wild-type and AID-KO BALB/cJ mice.  
Kaplan-Meier survival plots for MMTV-WT-infected wild-type BALB/cJ (blue) and AID-
KO (red) mice (left panel) as well as MMTV-SD-infected wild-type BALB/cJ (green) and 
AID-KO (purple) mice (right panel) showed no significant difference (p-values are shown). 
 
 
To determine the effect of AID ablation on proviral mutagenesis, proviruses were 
analyzed from five independent MMTV-WT and MMTV-SD tumors. Total cellular DNA 
was extracted, cloned with env-specific primers, and the resulting clones were subjected to 
Sanger sequencing. Although G to A mutations showed an increase in MMTV-SD 
compared to MMTV-WT proviruses, C to T mutations did not show the increase observed 
in wild-type BALB/cJ (Table 3.6 vs Table 3.1). As expected, the increase in AID-specific 
WRC motif mutations was abolished. Surprisingly, the fold-increase in TYC motifs typical 
of mA3-induced mutations was also abolished. Further, SYC motifs described as AID 
“cold-spots” [203, 204], showed the highest fold increase. 
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Table 3.6: Mutation frequency in MMTV-WT and MMTV-SD proviruses from 
AID-KO BALB/cJ mammary tumors by Sanger sequencing. 
1 Mutations/number of clones.  Based on Sanger sequencing of 1,100 bp of the plus-
strand of the proviral env gene clones obtained from five independent BALB/cJ AID-KO 
tumors induced by MMTV-WT (n=25) or MMTV-SD (n=40). The MMTV-SD clones 
analyzed retained the original SD mutation. 
 
I also examined the number of proviral clones with reversion of the SD-site 
mutation as well as the distribution of mutations in different clones. Interestingly, 62.5% 
of the clones from MMTV-SD proviruses had reversion of the original SD mutation. This 
result is considerably higher than the percentage (22%) of clones obtained from MMTV-
SD proviruses from mammary tumors appearing in wild-type BALB/cJ mice. One 
interpretation is that MMTV-SD replicates and recombines with endogenous Mtvs in a cell 
type enriched in AID-KO mice. The distribution of mutations/clone was not significantly 
different between the mutant and recombined MMTV-SD proviruses in WRC, TYC and 
ATC motifs (Figs. 3.17A, C and D). In contrast to results from MMTV-infected BALB/cJ 










G to A 0.80 1.65 2.1 
A to G 0.56 0.75 1.3 
C to T 0.12 0.10 0.8 
T to C 0.64 1.28 2.0 
Transition 2.12 3.78 1.8 
Transversion 0.20 0.25 1.3 
WRC 0.08 0.08 1.0 
SYC 0.08 0.72 9.0 
TYC 0.64 0.28 0.4 
ATC 0.12 0.32 2.7 
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MMTV-SD recombined proviruses (Fig. 3.17B). This result suggests that activity within 
the SYC motif is not due to AID, unlike reported previously [203, 204]. 
 
 
                 
  
 
Figure 3.17: Mutational analysis of the proviral envelope gene from AID-KO BALB/cJ 
mammary tumors induced by MMTV-WT or MMTV-SD.   
Number of C mutations within different motifs on either proviral strand is given for each 
clone. Clone numbers (n) are indicated.  Sequences were obtained from independent clones 
from five tumors in different animals. (A) Number of mutations/clone in the WRC motif 
typical of AID mutation hotspots. (B) Number of mutations/clone in the SYC motif. (C) 
Number of mutations/clone in the TYC motif typical of mA3 mutation hotspots. (D) 
Number of mutations/clone in the ATC motif. Statistical significance by non-parametric 
Mann-Whitney tests is indicated on the scatter plots.   
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Due to the lack of mutations in MMTV-SD recombinants recovered from tumors 
in AID-KO mice, correlation coefficients could not be calculated for WRC, TYC, and ATC 
motifs (Figs. 3.18 A, C and D).  The correlation between SYC motif mutations and 
reversion of the SD site was however maintained in AID-KO mice (Fig. 3.18B). These data 
suggested that mutations in the SYC motif resulted from the activity of a deaminase distinct 
from AID. 
 
            
Figure 3.18: Correlation analysis of the number of recombinants and sum of mutations in 
different sequence motifs within MMTV-SD proviruses from BALB/cJ AID-KO 
mammary tumors.  
(A, C and D) Spearman’s correlation coefficient (r) could not be calculated between the 
number of recombinants and the number of mutations in WRC, TYC and ATC motifs, 
respectively, due to lack of mutations in SD recombinants. (B) Spearman’s correlation 
coefficient (r) indicating high correlation between number of recombinants and number of 
mutations in SYC motif. Correlation coefficient p-values are shown on the graph. 
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Mutations within different sequence motifs were compared between MMTV-WT 
proviruses from mammary tumors in wild-type BALB/cJ mice and those in AID-KO mice. 
Direct analysis of the distribution of proviral mutations in the presence and absence of AID 
(Figs. 3.19 A-D) revealed that none were significantly different.  In contrast, the 
distribution of mutations/clone in WRC and TYC motifs within MMTV-SD proviruses 
(MMTV-SD mutants and MMTV-SD recombinants combined) significantly declined in 
AID-KO mice compared to wild-type BALB/cJ. On the other hand, analysis of distribution 
of mutations/clone showed a significant increase within the SYC motif in MMTV-SD 
proviruses obtained from mammary tumors in AID-KO mice.  Only mutations in the ATC 
motif showed a marginal, but insignificant, decline when comparing number of proviral 
MMTV-SD mutations/clone between BALB/cJ and AID-KO mice (p = 0.08) (Fig. 3.19D).   
These results are consistent with the interpretation that the absence of Rem 
expression leads to increased mutations by AID and potentially other deaminases during 
MMTV transmission in vivo. Thus, the effect of loss of Rem on MMTV proviruses is 
similar to HIV-1 proviral hypermutation mediated by human APOBEC3 in the absence of 





Figure 3.19: Comparisons of the distribution of mutations/clone within the proviral 
envelope gene between MMTV-WT and MMTV-SD-induced mammary tumors in either 
wild-type or AID-KO BALB/cJ mice.  
Number of C mutations within different motifs on either proviral strand is given for each 
clone. Number of clones (n) is indicated.  Sequences were obtained from independent 
clones from five tumors in different animals. (A) Number of mutations/clone in the WRC 
motif typical of AID mutation hotspots. (B) Number of mutations/clone in the SYC motif. 
(C) Number of mutations/clone in the TYC motif typical of mA3 mutation hotspots. (D) 
Number of mutations/clone in the ATC motif. Statistical significance by non-parametric 





3.2.5 AID is not incorporated into MMTV virions. 
 Specific human APOBEC3 proteins are packaged within budding HIV virions and 
restrict infection in target cells by deaminating negative-strand viral DNA during reverse 
transcription [97]. However, Vif expression in the producer cells targets APOBEC3 
proteins for proteasomal degradation, thereby preventing their incorporation in the viral 
particle [153, 207]. Since murine AID belongs to the Apobec family, tha ability of mAID 
to restrict MMTV by the same mechanism was tested. The mA3 enzyme is packaged in 
MMTV particles isolated from virus-containing milk [179]. Thus, packaging of mA3 was 
used as a positive control for packaging of mAID.  
 To confirm packaging of mA3, 293T cells were co-transfected with CMV-
driven MMTV expression plasmid (1 ug) and C-terminally HA-tagged mA3 plasmid (2 
ug) using Lipofectamine 3000. Virus released from 293T cells was concentrated 100X with 
Takara RetroX concentrator. Western blotting was performed on concentrated virus before 
and after treatment with subtilisin to remove cellular proteins on the surface of virions. 
MMTV Gag-specific antibody detected capsid proteins in both cell extracts and in the 
concentrated supernatants (Fig. 3.20A, upper panel). As expected, an mA3-specific band 
was observed in cell extracts and in supernatants (Fig. 3.20A, lower panel).  The presence 
of mA3 remained detectable after subtilisin treatment, confirming that mA3 is present 
within viral cores [179].   
Similar experiments were performed to determine whether AID was packaged in 
MMTV particles by co-transfection of CMV-MMTV and murine AID (mAID) into 293T 
cells.  Enrichment of the cleaved Gag protein was easily observed in cell supernatants 
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containing virion particles compared to extracts (Fig. 3.20B, upper panel).  Western 
blotting with AID-specific antibody detected mAID in cell extracts, but not in cell 
supernatants (Fig. 3.20B, lower panel). These experiments suggest that mAID is not 
incorporated into wild-type MMTV virions.  
 
        
 
Figure 3.20: mAID is not incorporated into MMTV virions. 
(A) mA3-HA is detectable in MMTV virions. Cells (293T) were co-transfected with 
MMTV and mA3-HA expressing plasmids. Western blots for both cell extracts (C.E.) and 
the 100-fold concentrated cell supernatant (-/+ subtilisin) are shown. Blots were incubated 
with either MMTV CA-specific (upper panel) or HA-specific (lower panel) antibody. (B) 
AID is not detectable in MMTV virions. Cells (293T) were co-transfected with MMTV 
and AID expressing plasmids. Western blots for both cell extracts (C.E.) and the 100-fold 
concentrated cell supernatant (-/+ subtilisin) are shown. Blots were incubated with either 






3.2.6 Rem causes proteasomal degradation of mAID. 
 HIV Vif is known to act as an adapter for a Cullin E3 ligase, resulting in the 
polyubiquitination and proteasomal degradation of human APOBEC3F and 3G [97]. Since 
AID was not detectably packaged within MMTV, Rem expression may affect the 
intracellular levels of mAID. Human Jurkat T cells, which lack endogenous Mtvs that may 
express Rem, were co-transfected with C-terminally GFP-tagged mAID expression 
plasmid and either wild-type or Rem-null virus expression plasmid. Western blotting 
revealed that Rem expression led to drastically reduced mAID-GFP levels (Fig. 3.21A, 
compare lanes 1 and 3). In contrast, in the absence of Rem expression mAID-GFP levels 
were maintained (Fig. 3.21A, compare lanes 1 and 5).   
To confirm that Rem expression was responsible for decreased mAID levels, 
HEK293 cells were co-transfected with mAID-GFP and either N-terminally GFP-tagged 
Rem or untagged Rem plasmid.  The presence of tagged or untagged Rem proteins lowered 
expression of mAID (Fig. 3.21B; compare lanes 1 and 3 or 5), whereas mAID levels were 
rescued in the presence of the proteasomal inhibitor MG-132 (Fig. 3.21B, even lanes). As 
previously reported, GFP-Rem precursor levels were stabilized by MG-132 compared to 
the cleaved product GFP-SP due to precursor susceptibility to endoplasmic reticulum-
associated degradation (ERAD) (compare lanes 5 and 6) [24].  These results are consistent 
with a Vif-like activity of Rem.   
Since mutations in mA3-specific TYC motifs were also higher in proviruses from 
Rem-null virus-induced tumors (Tables 3.1 and 3.2, Figs. 3.7 and 3.13), HEK293 cells 
were co-transfected with Rem expression vectors in the presence of plasmids expressing 
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mAID-GFP or mA3 C-terminally tagged with HA (mA3-HA).  As expected, higher Rem 
levels led to a greater reduction of mAID levels (Fig. 3.21C, compare lanes 1-3). In 
contrast, the same Rem concentrations had no effect on mA3 expression (Fig. 3.21C, 
compare lanes 4-6).  Thus, these data indicate that mAID is targeted for proteasomal 
degradation in the presence of Rem, whereas mA3 is not.   
     
Figure 3.21: Rem antagonizes mAID.  
(A) Co-transfection of Rem-expressing provirus leads to reduced mAID-GFP levels, 
whereas a Rem-null provirus does not. Either TBLV-WT or TBLV-SD expression plasmid 
was transfected into Jurkat cells in the presence or absence of murine AID tagged with 
GFP.  Western blots were performed with GFP-specific (upper panel) or actin-specific 
(lower panel) antibody.  (B) Rem expression leads to decreased mAID-GFP levels and is 
dependent on the proteasome. Cells (293) were co-transfected with expression plasmids 
for mAID-GFP and either GFP-tagged or untagged Rem.  Samples in even lanes were 
prepared from cells treated with the proteasomal inhibitor MG-132. Western blots of cell 
extracts were incubated with GFP- or actin-specific antibody (upper and lower panels, 
respectively). (C) Rem expression does not affect mA3-HA levels. Cells (293) were 
transfected with the indicated amount of mAID-GFP expression vector or mA3-HA in the 
presence or absence of the indicated amount of untagged Rem expression plasmid. One 
blot (upper left) was incubated with GFP-specific antibody, whereas another blot (upper 
right) was incubated with HA-specific antibody.  Actin-specific antibody (lower panels) 
was used to verify equal levels of protein loading. These results were obtained by Drs. 
Hyewon Byun and Frank Medina. 
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Taken together, these results are consistent with the interpretation that Rem protein 
is required for antagonizing the mutagenic effects of AID during MMTV replication prior 
to mammary gland transmission. Further mechanistic experiments are required to 
understand the stage of the MMTV life cycle for interactions with cellular Apobec 
enzymes. Moreover, the cellular compartment and host components needed for Rem 
















Chapter 4:  Apobec Enzyme Editing of Proviruses in TBLV-Induced T-
Cell Tumors from C57BL/6 mice 
 
4.1 RATIONALE 
Studies in BALB/cJ mice showed that Rem antagonizes AID-associated proviral 
hypermutation, and also potentially the activity of other members of the Apobec family. 
Proviruses obtained from MMTV-SD (Rem-null)-injected BALB/cJ mice had increased 
mutations compared to MMTV-WT injected mice (Table 3.1 and Fig. 3.7). These 
mutations were observed in AID-specific WRC motifs as well as mA3-specific TYC 
motifs, and in two other motifs – ATC and SYC. In addition to Rem, the SD-site mutation 
also abolishes expression of sag transcript from the intragenic env but not the upstream 
LTR promoter [185]. Further, increased mutations were observed in TBLV-SD proviruses 
isolated from BALB/cJ T-cell tumors (Table 3.2 and Fig. 3.13). Since TBLV is a Sag-
independent virus [70], increased proviral mutations were attributed to loss of Rem, not 
Sag expression. Also, transfection experiments showed that Rem co-expression leads to 
proteasomal degradation of AID (Fig. 3.21). MMTV requires replication in both B and T 
cells [30], which express AID and mA3. Therefore, viral genome hypermutation was 
analyzed after inoculation of MMTV-WT or MMTV-SD into AID-KO mice on the 
BALB/cJ background. Interestingly, the difference between MMTV-WT and MMTV-SD 
proviral mutations within both WRC and TYC motifs disappeared on the AID-KO 
background (Table 3.6, Fig. 3.17 and Fig. 3.19). Together, these results indicated that Rem 
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C-terminal sequences are critical for MMTV to antagonize Apobec family cytidine 
deaminases in BALB/cJ mice. 
Mouse genetics have provided many important insights into the biology of viruses 
and the anti-viral immune response, including innate immunity mediated by Apobec family 
members [167-171]. Experiments using the RIII strain of MMTV to infect C57BL/6 (B6) 
mice were the first to show inhibition of retroviral replication and tumorigenesis by Apobec 
enzymes in vivo [179]. Interestingly, MMTV hypermutation was not observed in the 
presence or absence of mA3 [179]. Due to the availability of sequence data and ease of 
manipulating mouse genes, many of the engineered mouse strains are on the B6 
background. Nevertheless, published data indicate that the levels of Apobec enzymes vary 
between BALB/c and B6 mice [180]. To further understand the involvement of cytidine 
deaminases in MMTV replication within various lymphocyte populations and in different 
mouse strains, I conducted additional experiments using the Sag-independent TBLV-WT 
virus and the Rem-null mutant (TBLV-SD) in B6 mice.  
4.2 RESULTS 
4.2.1 Tumors induced by Rem-null virus are accelerated in µMT B6 mice. 
No difference in tumor incidence or latency was observed in BALB/cJ mice 
inoculated with TBLV-WT or Rem-null TBLV-SD, yet TBLV-SD-induced tumors had a 
decreased proviral load and increased mutations in WRC (AID-specific), TYC (mA3-
specific), ATC and SYC motifs (Figs. 3.11 and 3.13).  I sought to confirm this mutational 
phenotype in B6 mice, so that further studies could be performed in different mApobec 
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knockout strains on the B6 background to delineate the cell types and deaminases involved 
in mutating the viral genome in the absence of Rem. B6 mice lack the MHC class II I-E 
gene required for efficient C3H MMTV–Sag presentation and are thus less susceptible to 
MMTV infection [215]. Hence, TBLV, a Sag-independent variant of MMTV, which causes 
T-cell lymphomas in many mouse strains [51, 54, 55], was used for this study.  
Wild-type B6 mice were injected intraperitoneally with 2 x 107 Jurkat cells 
expressing TBLV-WT or TBLV-SD (Rem-null) virus. Inoculation of TBLV-SD gave a 
slightly increased latency compared to TBLV-WT injection in B6 mice, which did not 
reach statistical significance (Fig. 4.1). Unlike BALB/cJ, in which 50% mice developed 
tumors (Fig. 3.11), almost all B6 mice developed tumors at the same dose of injection. This 
result suggests that B6 mice are more susceptible to TBLV infection. To confirm this 
observation, B6 mice were inoculated with 5x105, 4x106, and 2x107 Jurkat cells producing 
TBLV-WT or TBLV-SD.  As anticipated, the dose for B6 mice, which most closely 
approximated the tumor incidence in BALB/c animals, was 5x105 TBLV-infected cells.  
Thus, the comparable dose for B6 mice was ~40 times lower than that for BALB/c (Table 




                      
Figure 4.1: Kaplan-Meier plots for T-cell lymphoma development in B6 mice injected with 
TBLV-WT (blue line) or TBLV-SD (green line).  
B6 mice develop T-cell tumors with a similar incidence and latency after infection with the 
Rem-null (TBLV-SD) virus (the p-value was marginal, but did not reach a statistically 
significant value of 0.05). 
 
Table 4.1: T-cell lymphoma incidence in wild-type B6 mice at varying doses of virus 
injection. 
 
 1 Mice were injected intraperitoneally with Jurkat cells stably expressing TBLV-WT or   






Number of cells 
injected1 
Tumor Incidence Average Latency 
TBLV-WT 2x107 100% 4 months 
TBLV-SD 2x107 100% 4 months 
TBLV-WT 4x106 75% 4 months 
TBLV-SD 4x106 90% 3.3 months 
TBLV-WT 5x105 50% 5 months 
TBLV-SD 5x105 41% 5.5 months 
 84 
 
To determine proviral hypermutation by Apobec enzymes, T-cell lymphomas were 
harvested from three independent TBLV-WT-induced tumors and an equal number of 
TBLV-SD-induced tumors (both groups injected with 2x107 virus-producing cells).  DNA 
extracted from these tumors was amplified using TBLV-specific primers and an env-LTR-
specific PCR product was cloned. Individual clones were analyzed by Sanger sequencing. 
Sequencing results for the proviral plus strand are shown (Table 4.2). Contrary to results 
from TBLV infection in BALB/cJ mice (Table 3.2), differences between wild-type and 
Rem-null TBLV genome hypermutation generally were not observed in B6 mice, perhaps 
due to a dose of virus yielding a 100% tumor incidence. Nevertheless, similar to BALB/c 
mice, the frequency of ATC was increased for TBLV-SD proviruses (5-fold for B6 mice 
versus 2.6 fold for BALB/c mice). Mutational analysis of the viral genome will be repeated 
in this strain using a viral dose that results in a tumor incidence comparable to that observed 









Table 4.2: Mutation frequency in TBLV-WT and TBLV-SD proviruses from B6 
thymic tumors by Sanger sequencing. 
          1 Mutations/number of clones.  Based on Sanger sequencing of 1,100 bp of the  
       plus strand of the proviral env gene clones obtained from three independent  
       B6 tumors induced by TBLV-WT (n=50) or TBLV-SD (n=53).  
 
My previous data indicate that Rem-null MMTV and TBLV proviruses have 
increased WRC-motif mutations typical of AID relative to their respective wild-type 
proviruses in tumors from BALB/cJ mice (Tables 3.1 and 3.2). To determine if TBLV, like 
MMTV, requires replication in mature B cells where AID levels are reportedly the highest 
[216], C57BL/6 µMT (immunoglobulin heavy chain-knockout) mice and wild-type B6 
mice were infected with TBLV-WT or TBLV-SD. This strain was developed by 
introducing a neomycin resistance cassette to disrupt one of the membrane exons of the 
gene encoding immunoglobulin heavy chain of the class IgM [220]. No expression of 
membrane-bound IgM is detectable together with a lack of peripheral B cells, although 
some B cells may be produced using a heavy-chain constant region gene other than IgM 
[221]. TBLV-WT gave a similar tumor incidence and latency as that observed for wild-










G to A 3.06 4.34 1.4 
A to G 0.96 1.79 1.9 
C to T 0.72 1.04 1.4 
T to C 1.10 1.32 1.2 
Total Transition 5.84 8.49 1.5 
WRC 0.42 0.64 1.5 
SYC 0.36 0.53 1.5 
TYC 2.26 2.89 1.3 
ATC 0.22 1.10 5.0 
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significant acceleration of T-cell tumors induced by TBLV-SD virus (Fig. 4.3). These 
results indicate that TBLV does not require replication in mature B cells for tumor 
induction in T cells.  
To directly test the effect of AID on tumor development by TBLV in B6 mice, 
C57BL/6 AID-KO mice were also injected with 2x107 TBLV-WT or SD-expressing Jurkat 
cells. No difference in latency or incidence was observed in TBLV-WT infected mice (Fig. 
4.2). Unlike µMT mice, TBLV-SD did not display a significantly different tumor incidence 
or latency in AID-KO compared to the wild-type mice (Fig. 4.3). Lower doses of TBLV-
WT and SD are also being tested to more closely mimic the susceptibility of B6 mice to 
this virus relative to BALB/c mice. Nevertheless, TBLV-SD-induced T-cell tumors 
developed with a shorter latency in µMT mice. This acceleration of T-cell lymphomas was 
observed in TBLV-SD infected µMT, and not AID-KO mice. Previous studies that reported 
mA3 as a restriction factor for MMTV in B6 mice showed that wild-type virus-induced 
mammary carcinomas were accelerated in mA3-deficient mice [179]. If a mature B-cell 
specific cytidine deaminase restricts TBLV, wild-type virus-induced tumors are also 
expected to accelerate in µMT mice, unlike the result obtained (Fig. 4.2). Thus, the 
existence of a restriction factor that antagonizes only Rem-null TBLV, a Sag-independent 
virus, in µMT mice is not in agreement with the predicted effects of known MMTV 
restriction factors.  
 
 




   
 
 
Figure 4.2: Kaplan-Meier survival plots for TBLV-WT-infected wild-type (black), AID-
KO (green) and µMT (red) mice on B6 background.  
The incidence and latency of T-cell lymphomas showed no significant difference between 
the three B6 strains. All p values were > 0.05, as tested by Mantel-Cox Log-rank test. 
 







Figure 4.3: Kaplan-Meier survival plots for TBLV-SD-infected wild-type (black), AID-
KO (green) and µMT (red) mice on B6 background.  
The incidence and latency of TBLV-SD-induced T-cell lymphomas were significantly 
different only between wild-type and µMT B6 mice (p = 0.006). All other p values were 
> 0.05, as tested by the Mantel-Cox Log-rank test. 
 
Studies have shown that mature B cells are required for efficient MMTV 
transmission after milk-borne infection [193]. However, development of T-cell tumors in 
µMT mice suggests that the life cycle of the T-cell variant TBLV does not require virus 
trafficking through mature B cells. Acceleration of tumor development in TBLV-SD-
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infected µMT mice is unlikely due to lack of a good antibody response since this phenotype 
was not observed in TBLV-WT-infected µMT mice.  
I also considered whether differential selection for cis-acting elements known to 
affect TBLV disease induction [64, 65] could accelerate TBLV-SD induction of tumors in 
µMT mice after Apobec-mediated mutagenesis. Specifically, TBLV proviruses have a 
triplicated T-cell enhancer element within the LTR that increases viral transcription in T 
cells [70]. A previous study has shown that changes within this region are selected during 
tumor passage, with four and one-repeat elements being transcriptionally less active [66]. 
As expected, PCR performed with LTR-specific primers showed a predominance of 3-
repeat enhancers typical of the input virus. Further, no change in the number of enhancer 
repeats within TBLV-SD proviruses relative to TBLV-WT proviruses was observed in 
tumors from µMT mice that would confer an obvious selective advantage (Fig. 4.4).  
 
         
 
Figure 4.4: PCR analysis of LTR enhancer repeats from µMT B6 T-cell lymphomas 
induced by TBLV-WT or TBLV-SD.   
PCR was performed on DNA extracted from three independent T-cell tumors using LTR 




Sequencing results for the proviral plus strand from AID-KO and µMT mice 
showed that mutation frequency in the TYC motif was highest in all B6 strains (Tables 4.2, 
4.3 and 4.4). Mutations within TYC motif showed an increase in the absence of Rem in 
µMT but not AID-KO mice. This suggests that absence of AID affects mutations within 
TYC motif, similar to the result in MMTV-infected BALB/c AID-KO mice (Table 3.6). 
Moreover, these results imply that the cytidine deaminase or cell type responsible for TYC 
motif mutations is enriched in µMT mice. Since the mutation frequency in WRC motif was 
higher in the absence of Rem in AID-KO mice, perhaps an enzyme different from AID can 
target this motif. In addition, mutations within ATC motif did not show an increase in the 
absence of Rem only in µMT mice. This suggests that the enzyme catalyzing ATC motif 
mutations is expressed in mature B cells and is antagonized by Rem.  
 
Table 4.3: Mutation frequency in TBLV-WT and TBLV-SD proviruses from B6 
AID-KO thymic tumors by Sanger sequencing. 
 1 Mutations/number of clones.  Based on Sanger sequencing of 1,100 bp of the  
       plus strand of the proviral env gene clones obtained from three independent  











G to A 2.38 2.09 0.9 
A to G 0.58 0.6 1.0 
C to T 0.22 0.35 1.6 
T to C 0.78 0.65 0.8 
Total Transition 3.96 3.69 1.0 
WRC 0.16 0.60 3.8 
SYC 0.54 0.56 1.0 
TYC 1.58 1.42 0.9 
ATC 0.16 0.55 3.4 
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Table 4.4: Mutation frequency in TBLV-WT and TBLV-SD proviruses from B6 
µMT thymic tumors by Sanger sequencing. 
1 Mutations/number of clones.  Based on Sanger sequencing of 1,100 bp of the  
       plus strand of the proviral env gene clones obtained from three independent  
       B6 µMT tumors induced by TBLV-WT (n=50) or TBLV-SD (n=51).  
 
4.2.2 Rem-null virus-induced tumors have increased TYC consensus site mutations 
in µMT mice. 
To address the increase in susceptibility of µMT mice to Rem-null virus, the 
mutational profile of the proviral genome was compared between tumors induced in wild-
type and µMT mice. Although AID is known to be responsible for antibody affinity 
maturation in germinal center B cells, AID catalyzed SHM and CSR have been 
demonstrated in immature B cells as well [216]. AID expression has also been shown to 
be important for purging autoreactive B-cells from the immune repertoire [217]. TBLV-
WT proviruses showed no significant difference in the distribution of WRC, SYC or ATC 
motif mutations between wild-type and µMT mice. TYC motif mutations typical of mA3 
were slightly higher in the absence of mature B-cells (Fig. 4.5) (p = 0.04), perhaps 
indicative of TBLV infection of a different cell type.  
The mutational profile of TBLV-WT proviruses from tumors induced in AID-KO 










G to A 3.74 7.59 2.0 
A to G 0.74 0.57 0.8 
C to T 0.54 0.43 0.8 
T to C 0.98 0.45 0.5 
Total Transition 6.00 9.04 1.5 
WRC 0.72 1.02 1.4 
SYC 0.52 0.69 1.3 
TYC 3.10 5.61 1.8 
ATC 0.40 0.41 1.0 
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type B6 mice. A significant decrease was observed in the WRC motif mutations by 
examination of the distribution of mutations/clone. Unlike the µMT mice, the distribution 
of TYC motif mutations/clone in TBLV-WT proviruses from wild-type and AID-KO 
tumors was unchanged (Fig. 4.6) 




Figure 4.5: Comparison of the distribution of mutations within the proviral envelope gene 
from wild-type and µMT thymic tumors induced by TBLV-WT on the B6 background.  
Independent cloned sequences were obtained from three tumors in different animals. 
Number of C mutations within different motifs on either proviral strand is given for each 
clone. Statistical significance by non-parametric Mann-Whitney tests is indicated on the 
scatter plots.   
 




                  
                              
Figure 4.6: Comparison of the distribution of mutations within the proviral envelope gene 
from wild-type and AID-KO thymic tumors induced by TBLV-WT on the B6 background.  
Independent cloned sequences were obtained from three tumors in different animals. 
Number of C mutations within different motifs on either proviral strand is given for each 
clone. Statistical significance by non-parametric Mann-Whitney tests is indicated on the 
scatter plots.   
 
Next, mutations in all motifs were compared between TBLV-SD proviruses 
isolated from the three strains of mice. Distribution analysis revealed that mutations/clone 
in the ATC motif were reduced in µMT mice, which could be due to the absence of a 
cytidine deaminase specific for mature B cells. However, mutations/clone in the TYC motif 
were highly enriched in µMT mice compared to those from wild-type B6 mice, presumably 
due to increased transmission of virus through T-cells in mature B-cell deficient mice (Fig. 
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4.7). Taken together, these results fail to explain how tumors are accelerated in Rem-null 
infected µMT mice.  
 
                       
                    
Figure 4.7: Comparison of the distribution of mutations within the proviral envelope gene 
from wild-type and µMT thymic tumors induced by TBLV-SD on the B6 background.  
Independent cloned sequences were obtained from three tumors in different animals. 
Number of C mutations within different motifs on either proviral strand is given for each 
clone. Statistical significance by non-parametric Mann-Whitney tests is indicated on the 
scatter plots.   
 
TBLV-SD proviruses from T-cell lymphomas in AID-KO mice on the B6 
background also were examined for different motifs targeted by cytidine deaminases.   
Distribution analysis revealed that both TYC and ATC motif mutations/clone were 
decreased significantly (Fig. 4.8).  Unlike the mutational pattern for TBLV-WT, no 
significant difference was observed for the AID target motif, WRC. This mutational pattern 
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was compared to the analysis of MMTV-WT and MMTV-SD (Rem-null) proviruses in 
BALB/c AID-KO mice (Table 3.4 and Fig. 3.17).  The absence of both AID and Rem in 
each situation reduced mutations in the WRC motif, but also unexpectedly reduced TYC 
and ATC motif mutations. 
 
 
                       
Figure 4.8: Comparison of the distribution of mutations within proviral envelope gene from 
wild-type and AID-KO thymic tumors induced by TBLV-SD on the B6 background.  
Independent cloned sequences were obtained from three tumors in different animals. 
Number of C mutations within different motifs on either proviral strand is given for each 
clone. Statistical significance by non-parametric Mann-Whitney tests is indicated on the 
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4.2.3 Splenocytes from AID-GFP transgenic mice on B6 background can be 
stimulated ex vivo to induce and monitor AID expression.  
Proviruses isolated from MMTV and TBLV-induced tumors harbored mutations in 
previously characterized as well as uncharacterized motifs. In both cases, viral genomes 
were analyzed for mutations in tumor-bearing cells. Induction of MMTV-induced 
mammary carcinomas likely occurs long after virus encounters restriction by deaminases 
during virus amplification in the lymphocyte population [30]. Thus, mechanistic 
understanding of the involvement of cytosine deaminase enzymes in retrovirus restriction 
can be better achieved with a tissue-culture system in which specific lymphocyte 
populations can be sorted at earlier time-points post-infection.  
Rem-null proviruses showed mutations within motifs that are not specific for AID 
activity (non-WRC), suggesting that other deaminases can mutate the proviral genes (Table 
3.1). However, mutations within the non-WRC motifs were reduced in AID-KO BALB/cJ 
mice (Table 3.6). This raises the possibility that AID acts on non-WRC motifs unlike 
previously published data for immunoglobulin genes [202]. Expression of AID has been 
reported outside of GC B cells [128, 216, 217]. Thus, using GFP as a marker will facilitate 
sorting for AID-expressing and non-expressing cells. C57BL/6 AID-GFP mice have been 
obtained from the Jackson Laboratory [218]. The GFP-sorted cells can be independently 
analyzed for mutations within all motifs to determine if non-WRC mutations are observed 
in MMTV proviruses only in cells not expressing AID.  
To confirm that AID expression could be induced and monitored, splenocytes were 
obtained from an Aicda-gfp positive animal confirmed by genotyping of tail DNA as 
described [218].  Splenocytes were cultured in media containing lipopolysaccharide (LPS) 
and interleukin-4 (IL-4), and AID expression in cell lysates was confirmed at day 5 and 
day 10 by Western blotting (Fig. 4.9A). Incubation with AID-specific antibody yielded a 
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50 kDa band corresponding to AID-GFP in cells grown in stimulation media. A weaker 24 
kDa band was observed with the expected size of endogenous mAID. These results 
suggested that the levels of AID-GFP are much higher than the endogenous AID protein, 
although it is not clear whether GFP tagging will affect hypermutation of MMTV 
proviruses.  
Splenocytes from two independent AID-GFP positive mice were analyzed by flow 
cytometry using BD LSRII Fortessa Flow Cytometer to confirm GFP expression in induced 
splenocytes (Fig. 4.9B). An AID-GFP negative littermate was used as a control. Flow 
cytometry analysis suggested that there were two different populations of GFP-positive 
cells. Further characterization will be required to determine if both populations of cells are 
infected with MMTV and subjected to hypermutation.  
 
 
           
Figure 4.9: Induction of mAID in AID-GFP C57BL/6 transgenic mice.  
(A) Splenocytes from AID-GFP positive mice were grown in regular media (lane 1) or 
media containing LPS and IL-4 (lanes 2 and 3) to induce AID. Lysates were analyzed by 
Western blotting with AID-specific antibody. A lysate from AID-GFP transfected 293T 
cells was used as a positive control (lane 4). (B) Splenocytes from AID-GFP negative (red) 
and positive littermates (green and blue) were grown in stimulant media for 4 days and 
analyzed by flow cytometry.  
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Chapter 5:  Discussion and Perspective 
5.1 MMTV REM ANTAGONIZES ACTIVATION-INDUCED CYTIDINE DEAMINASE (AID). 
 
MMTV-Rem is a precursor that specifies an N-terminal Signal Peptide (SP), which 
is also generated by cleavage from envelope (Env) protein to serve a Rev-like function 
[24]. The role of the remaining Rem C-terminal sequences has not been described, but has 
been shown to be dispensable for virus replication in XC cells [185]. Therefore, I 
considered whether Rem C-terminal sequences serve an accessory function that facilitates 
MMTV replication in vivo.  
 Prior studies have revealed that the incidence of mammary tumors and viral loads 
were higher in mice deficient for mA3 [179]. However, no MMTV-encoded factor that 
antagonizes mA3 has been identified. Deaminases belonging to the Apobec family are 
expressed in B and T cells, both of which are required by MMTV for efficient transmission 
to the mammary gland [193, 25]. The potential role of Rem C-terminal sequences to 
counteract Apobec-mediated restriction of MMTV replication was assessed. 
The Rem-null MMTV (MMTV-SD) was engineered as a splice donor mutant, 
which altered a single amino acid in envelope protein and eliminated production of spliced 
rem mRNA (Fig. 3.3B) as well as spliced sag mRNA from the intragenic env promoter 
[185]. Because the single amino acid change in Env did not affect viral RNA or protein 
production in rat XC cells [185] or virus release from human Jurkat cells (Fig. 3.10), the 
major effects of the splice donor mutation are likely due to failure to express either sag 
mRNA or rem mRNA or both. Therefore, two different viruses, the Sag-dependent MMTV 
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that causes mammary tumors [185] and the Sag-independent virus that induces T-cell 
lymphomas (TBLV) [70] were used to determine whether Rem is an Apobec antagonist.  
Experiments conducted with wild-type and Rem-null MMTV demonstrated that 
Rem C-terminal sequences are needed for antagonism of the mutagenic effects of mAID. 
Multiple lines of evidence support this conclusion. First, tumors induced by wild-type 
MMTV had higher proviral loads than tumors induced by Rem-null virus (MMTV-SD) 
(Fig. 3.6B). Second, the number of C to T transitions and mutations within the AID-specific 
WRC motif were enriched in proviruses obtained from tumors induced by MMTV-SD 
compared to MMTV-WT in wild-type BALB/cJ mice (Table 3.1).Third, the difference in 
proviral load was abolished in tumors induced by MMTV in AID-KO BALB/cJ mice (Fig. 
3.15B). Fourth, increased C to T transitions and WRC mutations were not observed in 
MMTV-SD proviruses from AID-KO BALB/cJ mice (Table 3.6 and Fig. 3.19A).  Fifth, 
the Sag-independent variant TBLV [70] also showed lower proviral load and increased 
WRC-motif mutations in tumors induced by the cognate Rem-null virus (Fig. 3.11B and 
Table 3.2). Sixth, Rem co-expression led to proteasomal degradation of AID (Fig. 
3.21).  These results support the idea that Rem antagonizes AID during virus replication in 
lymphoid cells prior to mammary gland transmission.  
Both tumor incidence and proviral loads were significantly reduced in Rem-null 
MMTV-injected BALB/cJ mice. On the other hand, BALB/cJ AID-KO mice lost the 
difference in proviral loads, but maintained the difference in tumor incidence. One possible 
explanation is that proviral loads are a Rem-dependent phenomenon since the absence of  
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Rem allows accumulation of mutagenized proviruses, which affects virus production. On 
the other hand, tumor incidence may be attributed to reduced Sag production from MMTV-
SD [185] and decreased virus amplification in the lymphoid cell population. Lymphoma 
induction by the Sag-independent TBLV was unaffected by Rem expression relative to 
induction by TBLV-WT, but proviral loads were reduced in Rem-null TBLV-induced 
tumors. These data suggest that Rem expression increases the infectivity of viruses released 
from B and T cells prior to Sag-mediated transmission to the mammary gland.   
The mutational phenotype of MMTV-SD proviruses in BALB/cJ mice also 
suggests the role of Rem C-terminal sequences in antagonizing mA3. In addition to the 
WRC motif, mutations within the mA3-specific TYC motif were also enriched in Rem-
null virus induced tumors (Tables 3.1 and 3.2).  Surprisingly, proviral mutation differences 
in both WRC and TYC motifs disappeared in tumors from AID-KO BALB/cJ mice (Table 
3.6 and Fig. 3.19). Although TYC motif mutations are considered to be a result of mA3 
activity, AID may cause these mutations as well. However, statistical analysis of 
distribution of mutations/clone in wild-type BALB/cJ mice showed that cytidine 
deamination within TYC motifs was elevated in tumor-derived MMTV-SD proviruses, 
regardless of SD-site recombination. On the other hand, cytidine deamination within 
proviral WRC motifs was selectively elevated only after SD-site recombination (Fig 3.7). 
Thus, a more likely interpretation is that TYC and WRC mutations occur in different cell 
types, and that AID ablation skews the abundance of cell types where MMTV replication 
occurs prior to infection of the mammary gland. Hence, the data also predict that AID has  
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direct or indirect effects on mA3-mediated mutagenesis of MMTV proviruses. Since both 
AID and hA3G independently form RNA-dependent high molecular mass (HMM) 
complexes in the cytosol [222, 223], it is possible that mAID and mA3 are part of the same 
complex. In that case, absence of mAID in AID-KO BALB/cJ mice will impact the 
expression or activity of mA3 and provide an explanation for the loss of mutations within 
the TYC motif. 
Absence of Rem in MMTV-SD and TBLV-SD proviruses also yielded increased 
mutations in the ATC motifs (Tables 3.1 and 3.2). In vitro experiments have reported the 
ATC motif as an mA3 target specifically in BALB/cJ mice [180]. However, the TYC and 
ATC motif mutations did not always follow the same distribution of mutations/clone. For 
example, TYC motifs were significantly mutated between MMTV-WT and SD non-
recombinants (proviruses than retained the SD-site mutation), whereas ATC motifs were 
not significantly altered when the same sets of clones were compared (Fig. 3.7). The same 
trend was observed when comparing the distribution of ATC motif mutations between 
TBLV-WT and SD-non recombinants (Fig. 3.13). These results suggest that TYC and ATC 
motif mutations may be due to different enzymes.  
Proviruses from MMTV-SD-induced mammary carcinomas in BALB/cJ mice 
lacked significant enrichment in the SYC motif mutations compared to the wild-type 
proviruses (Fig. 3.7). On the other hand, proviruses from AID-KO BALB/cJ mice showed 
an increase in SYC-motif mutations (Fig. 3.17) in Rem-null tumors. Previous studies report 
sequence changes within the SYC motif as “cold-spot” mutations by AID [203, 204]. My 
 102 
results imply that SYC-motif mutations on the MMTV provirus are due to the activity of 
another unidentified cytidine deaminase.  
Interestingly, mutations in all motifs were more enriched in proviruses that had 
repaired the SD mutation. BALB/cJ mice have three endogenous Mtv copies, Mtv6, 8 and 
9 [32]. Only Mtv8 and Mtv9 are complete proviruses that are expressed in lymphocytes 
[27]. The commonly observed “reversion” of the SD mutation at all 6 mutant bases likely 
occurs in B and/or T cells [28, 185, 205, 208].  Importantly, occurrence of such an event 
indicates a strong selection for the restoration of the env gene SD site, which results in 
production of either rem mRNA from the LTR promoter or sag mRNA from the 
intragenic env promoter [185, 209]. Since reversion was observed in proviruses obtained 
from tumors induced by both Sag-dependent MMTV and Sag-independent TBLV, the data 
argue that the recombination event occurs to allow expression of Rem, not Sag.  The 
frequency of SD-site reversion in TBLV-SD proviruses (9%) was lower than that in 
MMTV-SD proviruses (22%), likely due to the requirement for the original SD site 
exclusively for Rem production during of MMTV replication in B cells in vivo.  The 
likelihood is low that reversion occurs to promote wild-type envelope protein production 
since proviral loads in MMTV-SD and WT-induced tumors in AID-KO mice were the 
same (Fig. 3.15B), indicating no replication effect of the single amino-acid Env mutation.  
Rem production likely provides a selective advantage for virus replication in 
lymphocytes prior to Sag-mediated transmission to the mammary gland. A statistically 
significant correlation was found between the number of SD recombinants in both MMTV 
and TBLV proviruses and the number of mutations in WRC or TYC motifs (Fig. 3.14). 
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These data suggest that SD reversion by recombination with endogenous Mtvs and 
Apobec-induced mutations are occurring in cell types that are infected by both MMTV and 
TBLV. Moreover, MMTV recombinants in mammary tumor DNA had no stop codons in 
the env gene compared to TBLV recombinant proviruses in thymic tumors (compare Figs. 
3.8 vs 3.12), consistent with the need to select infectious MMTVs during multiple cycles 
of replication in mammary tissue prior to tumor induction. Further experiments analyzing 
viral genome mutation and recombination within proviruses, especially those isolated at 
earlier time points prior to mammary tumor induction, are required to determine the 
lymphocyte sub-type where Apobec-mediated deamination is occurring.  
Tissue culture experiments conducted with both tagged and untagged Rem 
expression plasmids showed drastic reduction in levels of AID in the presence of Rem. 
More importantly, these levels could be rescued by addition of the proteasomal inhibitor 
MG-132, strongly suggesting that Rem is a Vif-like factor that antagonizes the restriction 
factor AID (Fig. 3.21). Unlike AID, mA3 levels were not affected by Rem co-expression. 
Since TYC-motif mutations were reduced in AID-KO BALB/cJ mice, AID and mA3 may 
possibly be part of a larger Apobec complex. One possibility is that Rem-mediated 
degradation of AID yields an indirect effect on the stability of mA3. AID was not 
incorporated into MMTV virions, and increased viral genome mutation was not observed 
during in-vitro transfection experiments in AID-expressing Jurkat cells (Fig. 3.20 and 
Table 3.5). Hence, it is possible that upon infection, AID gains access to the MMTV 
genome following reverse-transcription. Nevertheless, these results represent the first AID-
mediated antagonism of a retrovirus in a deamination-dependent manner. 
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In summary, these data strongly suggest that the retroviral protein Rem is an 
MMTV-encoded antagonist of AID in mice. Infected B and T cells act as a reservoir for 
MMTV until mice reach puberty, and the virus has access to actively dividing mammary 
epithelial cells. Lack of Rem results in increased mutations of the viral genome in 
lymphocytes. Proviruses with non-lethal mutations get selectively transmitted to the 
mammary gland, leading to mammary tumor induction (Fig. 5.1). AID is best known for 
its role in adaptive immunity in response to infectious agents [93, 210, 211], yet also has 
been shown to be important for restricting replication of herpesviruses in B cells [134]. 
Since AID overexpression has been associated with multiple human cancers [212], 
particularly B-cell lymphomas [213, 214], elucidation of the Rem-mediated mechanism 
targeting AID for degradation may be useful for both treatment of human tumors [212, 









         
Figure 5.1: Proposed model for mApobec-mediated restriction of MMTV.  
MMTV is transferred from infected mothers to pups during lactation. Virus infects 
dendritic and B cells, perhaps in gut-associated Peyer’s patches. Superantigen expression 
on these antigen-presenting cells elicits a T-cell response that results in proliferation of 
infected lymphocytes. Rem-null viruses are subjected to increased mutations within 
WRC/TYC motifs by cytidine deaminases and undergo recombination with endogenous 
Mtvs. Viruses with non-lethal mutations are selected and transmitted to the mammary 









5.2 MECHANISM OF REM FUNCTION 
 
HIV Vif antagonizes proteins belonging to the human APOBEC family of cytidine 
deaminases by targeting them for proteasomal degradation [151-153]. This accessory 
protein protects the HIV genome from APOBEC-mediated mutagenesis in the target cells 
following infection. Tissue culture experiments demonstrated that Rem co-expression 
results in proteasomal degradation of mAID (Fig. 3.21). It is not clear whether the precursor 
Rem or cleaved Rem CT protein is responsible for AID antagonism. Uncleaved Rem is 
retrotranslocated to the cytoplasm, ubiquitylated and subjected to ERAD [24]. Upon 
cleavage, a small fraction of Rem-CT utilizes ERAD to retrotranslocate to the cytoplasm. 
Another portion of the protein leaves the ER but does not follow the typical secretory 
pathway [Wendy Xu, unpublished data]. The most stable levels of Rem-CT are seen in the 
ER. Thus, either full-length Rem or a portion of the cleaved Rem-CT may act as an adapter 
to target AID for degradation. Degradation of mA3 was not observed in the presence of 
Rem (Fig. 3.21). However, if AID and mA3 co-exist in a complex, Rem-mediated 
ubiquitylation of AID can result in destabilization of mA3 (Fig.5.2). Further experiments 
with Rem expression constructs that are resistant to cleavage will address the form of Rem 








Figure 5.2: Proposed model for Rem-mediated antagonism of AID.  
Rem is synthesized at the ER membrane and cleaved by signal peptidase into SP and Rem-
CT [24]. The Rem-CT cleavage product is glycosylated in the ER lumen, where a fraction 
is retrotranslocated for degradation by cytosolic proteasomes. Rem precursor protein is also 
ubiquitylated and subjected to ERAD. Retrotranslocated Rem or Rem-CT acts as a Vif-
like adaptor to enable addition of ubiquitin chains on AID in cytosolic complexes with 
mA3 and other Apobecs (X) causing proteasomal degradation of AID, thus inhibiting 










Human APOBEC proteins deaminate cytidines on the HIV genome by 
incorporating into budding HIV virions in the absence of Vif [135-140]. Studies have 
shown mA3 to be packaged into MMTV virions [179], but experiments conducted in tissue 
culture with wild-type MMTV expressing plasmid did not detect AID in the mature MMTV 
particles (Fig. 3.20). However, it remains unknown whether AID gains access to the 
budding viral particle in the absence of Rem expression. In this case, if AID is packaged 
within MMTV virions, Rem will be mechanistically analogous to HIV Vif protein. On the 
other hand, if AID is not incorporated within Rem-null MMTV, further experiments will 
be necessary to determine the stage of the virus life cycle when AID accesses the viral 
genome. Mutational analysis performed on proviruses from human Jurkat T cells stably 
expressing AID did not show increased viral genome mutation in the absence of Rem 
(Table 3.5). Since human Jurkat cells are not re-infected due to their failure to express the 
mouse TfR1 receptor for MMTV Env protein [64], absence of increased mutagenesis 
indicates that AID acts on MMTV in the target cell following reverse transcription, perhaps 
as part of the viral pre-integration complex (PIC). In vitro experiments will be conducted, 
both with inhibitors of viral reverse transcription and proviral integration, to determine the 




5.3 APOBEC ENZYME EDITING OF PROVIRUSES IN TBLV-INDUCED T-CELL TUMORS 
FROM C57BL/6 MICE 
Since Rem-null proviruses recovered from BALB/cJ mice had mutations in non-
WRC motifs (Tables 3.1, 3.2 and 3.6), experiments in mouse strains lacking mA3 or mA1 
would shed light on the role of non-AID cytidine deaminases in restricting MMTV. Most 
such single or double-knockout strains are on a C57BL/6 (B6) background. Therefore, 
experiments were conducted in wild-type B6 mice to confirm the mutational phenotype 
observed in BALB/cJ mice. Because B6 mice are unable to efficiently present C3H MMTV 
Sag due to a mutation in MHC class II genes [215], I used the Sag-independent virus, 
TBLV [70], for these studies. Surprisingly, the TBLV dose that gave a 50% tumor 
incidence in BALB/cJ mice resulted in a nearly 100% incidence in B6 mice (Figs. 4.1 and 
3.11A). The reason for this difference in susceptibility is not known, but these two strains 
have been reported to be immunologically distinct [219]. In response to pathogens, T cells 
from B6 mice preferentially produce Th1 cytokines with high interferon-gamma (IFN) 
and low interleukin (IL-4), whereas those from BALB/cJ produce Th2 cytokines with low 
IFN and high IL-4. Proviruses analyzed from B6 tumors inoculated at the high dose 
resulted in much smaller differences in the numbers of mutations/clone between TBLV-
WT and TBLV-SD proviruses compared to BALB/c tumor-derived proviruses (Table 4.2). 
Additional studies in the B6 strain are needed at a viral dose that results in an incidence 
and latency more comparable to that observed in BALB/cJ mice.  Such experiments may 
result in a mutational profile similar to that observed with TBLV infection of BALB/cJ 
mice (Table 3.2), where absence of Rem resulted in increased proviral gene mutations.  
The µMT B6 mice lacking mature B cells were injected with TBLV-WT or SD at 
the same time as the wild-type B6 strain. Similar experiments were performed in AID-KO 
B6 mice. No significant difference in tumor incidence or latency was observed after 
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inoculation of either knockout mouse strain compared to wild-type B6 mice after 
inoculation with TBLV-WT (Fig. 4.2). However, loss of mature B cells, but not AID, 
coupled with Rem deficiency accelerated the latency of T-cell lymphomas induced by 
TBLV (Fig. 4.3). These results suggest that Rem inhibits TBLV replication or its 
transmission to T cells, presumably during interactions with mature B cells, but this 
inhibition is independent of AID expression.  
Proviruses from µMT tumors had increased mutations/clone only in the mA3-
specific TYC motif within TBLV-WT proviruses relative to those obtained from wild-type 
B6 mice (Fig. 4.5). The same comparisons of TBLV-SD proviruses showed a highly 
significant increase in the number of TYC motif mutations/clone, but also a significant 
decrease in ATC motif mutations/clone (Fig. 4.7). As expected, TBLV-WT infected mice 
showed significantly fewer WRC motif mutations/clone in AID-KO B6 tumors, but the 
numbers of SYC, TYC and ATC mutations/clone were unaffected compared to those in 
wild-type B6 tumors (Fig. 4.6). The same analysis of TBLV-SD proviruses revealed no 
change in WRC motif mutations/clone between wild-type and AID-KO B6 mice, yet both 
TYC and ATC motif mutations/clone were significantly decreased (Fig. 4.8). These results 
may be due to altered transmission of TBLV through T cells as well as infection of different 
populations of B cells. 
Ex vivo experiments were conducted using splenocytes harvested from AID-GFP 
transgenic mice on B6 background. Splenocytes were be grown in tissue culture conditions 
for almost two weeks and stimulated with LPS and IL-4 to induce expression of GFP-
tagged AID. This was confirmed by Western blotting and flow cytometry (Fig. 4.9). Data 
from BALB/cJ mice indicates that mApobec-mediated viral genome hypermutation is 
occurring in the lymphocytes, likely long before tumor development. Thus, splenocytes 
isolated from AID-GFP-expressing transgenic animals injected with MMTV can be used 
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to study phenotypic changes during early stages of virus infection, such as (i) monitoring 
for AID expression in cells infected with wild-type compared to Rem-null MMTV, and (ii) 
analyzing proviral genome mutations in cells infected with wild-type and Rem-null 
MMTV. Different lymphocyte sub-populations can be sorted using GFP and other cell-
surface markers to determine whether mutations in certain motifs occur in specific cell 
types and whether these mutations lead to decreased virus infectivity.  
In summary, my in vivo studies combined with tissue culture experiments suggest 
that Rem is a Vif-like antagonist of multiple Apobec family enzymes. Future experiments 
in AID-GFP transgenic mice as well as in different mApobec knockout strains will help to 
delineate the specific cell types and enzymes involved in virus restriction as well as their 
















APOBEC        apolipoprotein B mRNA editing enzyme 
AID                 activation-induced cytidine deaminase 
APC                antigen presenting cell                
ARM  arginine-rich motif 
BIV                 bovine immunodeficiency virus 
CA   capsid 
CIS                  common integration sites 
Crm1  chromosome region maintenance 1 protein 
CsCl                cesium chloride  
CSR                class switch recombination 
CTE  constitutive transport element 
Cux1  CCAAT displacement protein 1 
Da   daltons 
DC                  dendritic cell 
DEPC             diethyl pyrocarbonate 
Dex                 dexamethasone 
DMEM  Dulbecco’s modified eagles medium 
DNA   deoxyribonucleic acid 
dNTP   deoxyribonucleotide triphosphate 
DTT   dithiothreitol 
DU   dUTPase 
EDTA  ethylenediamine tetraacetic acid 
EBV                epstein-barr virus 
Env   envelope 
ER  endoplasmic reticulum 
ERAD  endoplasmic reticulum-associated protein degradation 
ERGIC            ER-golgi intermediate compartment 
FBS                 fetal bovine serum 
FIV                  feline immunodeficiency virus  
Gag   group-specific antigen 
GAPDH  glyceraldehyde-3-phosphate dehydrogenase 
GC                  germinal center 
GR                  glucocorticoid receptor 
HBV                hepatitis B virus 
HERV  human endogenous retrovirus 
HIV  human immunodeficiency virus 
HPV   human papillomavirus 
HRE   hormone-responsive element 
HTLV  human T-cell leukemia virus 
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IL  interleukin 
IN   integrase 
KSHV             kaposi’s sarcoma herpes virus 
LB                   luria-bertani broth 
LINE               long interspersed nuclear elements 
LPS                 lipopolysaccharide 
LTR   long terminal repeat 
LUC   luciferase 
mA1                murine Apobec1 
mA3                murine Apobec3 
MA   matrix 
MEC               mammary epithelial cells 
MG   mammary gland 
MGE  mammary gland enhancer 
MHC               major histocompatibility complex 
miR                 micro RNA 
MMTV  mouse mammary tumor virus 
MuLV  murine leukemia virus 
Mtvr2              mouse mammary tumor virus receptor homolog 2 
NC   nucleocapsid 
NES  nuclear export sequence 
NLS   nuclear localization signal 
NoLS  nucleolar localization signal 
NRE   negative regulatory element 
ORF                open reading frame 
PAGE              polyacrylamide gel electrophoresis 
PBS                 phosphate-buffered saline 
PCR   polymerase chain reaction 
Pol                   polymerase 
PR   protease 
Rem   regulator of export of MMTV mRNA 
Rev                 regulator of virion expression 
Rfv3                recovery from friend virus 3 
RmRE  Rem-responsive element 
RNP                ribonucleoprotein 
RRE  Rev response element 
RNA   ribonucleic acid 
RPMI   Roswell park memorial institute 
RT   reverse transcriptase/ room temperature 
RT-PCR  reverse transcription-polymerase chain reaction 
Sag   superantigen 
SDS   sodium dodecyl sulphate 
SHM               somatic hypermutation 
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SINE               short interspersed nuclear elements 
SIV                 simian immunodeficiency virus  
SP  signal peptide 
SU   surface envelope protein 
TBLV              Type-B leukemogenic virus 
TCR   T cell receptor 
TfR1                transferrin receptor 1 
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